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ABSTRACT
HEPATITIS C TREATMENT:

COMMUNITY-BASED, MULTIDISCIPLINARY

APPROACH TO

AND IMPROVE

Hepatitis C is a major international health care dilemma, occurring frequently in
populations who

other health care

Hepatitis C is the most

common blood-borne infection and the ......aUH,.r; cause

liver disease

the

States

(U.S.), causing 10,000 -12,000 deaths per year. According to the Centers for Disease
Control and Prevention (2008), up to 3.9 million
virus (HCV) within
are unaware of

US. Estimates

are affected with the hepatitis C

that 75%

diagnosis, and of those, only one in

treatment. Some researchers suggest that all
be

IJ'-'V'lJl'-

affected with
people are

HCV

.,.rt

ATT", ..

residents born between 1946 and 1970

hepatitis C over a 5-year period.
HCV carries an estimated financial burden of $10.7 billion nationally, and

$377 million in Michigan

Barriers to treatment include the lack of qualified

healthcare providers and treatment programs; rigorous treatment regimens
medication

significant

effects; psychosocial challenges include mental illness; addiction;

ugnnatIzat],on; and
improve access and care

" . . .'.Ull'''''..,..., coverage. The purpose of this project was
individuals

hepatitis C

vi

an

area.
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1
INTRODUCTION

international
populations

dilemma and occurs frequently

from other

Disease

disparities. According to the

and Prevention (CDC, 2008),
C

within the

to

cause of liver

States (US)

is the

number rises to 1

hn".rtpn

12). Hepatitis Cis

one reason for liver transplantation,
(NIH, 2002). Hepatitis C is the most

according to the National Institutes

US and it

common blood-borne infection in

for

million people are affected with

million world-wide (World Health Organization [WHO],
"'_U.'-'H,'f'>

....;"""r.'~f"'""r~

with it an

financial

of 10.7 billion nationally (Wong, McQuillan, McHutchison, & Poynard, 2000)

377 million

Michigan alone (Michigan

Community

2010).
greatest burden

Wong et al. (2000) forecasted
between 2010 and 2019. Their ......""''''''1'.
and Nutrition
likely become a
McGarry et
1

(2011)

and 1970 over a

<AUU.HVH

were

on data trends in the National

Survey III

1998).

age-based
for hepatitis C for
period. Among

1

HCV would occur

102 million

estimates
the HCV are

<>rtr'r\1'~'rt

US residents born between
40 to 64

as

as 1.3 million are infected with
..."..,'ll",,",, this population could

current

__ ..,....... would identify only 427,000. This means

742,000

be diagnosed and treated if current
cost saving of age-based screening occurs with early
advance

of

to reduce the numbers of individuals progressing to

liver

transplantation, or death.
national guidelines exist for the treatment of the
and established treatment

individuals ..""".,,""

of

therapy. Estimates in the US today
C are offered or
treatment, those with
probability of worsening liver disease, and
systems are not meeting the

of

McIntyre, McLeod, Nathwani, & Dillon,

10).

of

to involve an integrated approach to care with
collaborating to address the many
treatment.
......r'rr .. ," ........

n<lTT1P1r<:

,,,,,,,v,,",,,,,,,",,,,

Extension for Community Healthcare Outcomes

ae'"elc)ne:a by the University of New Mexico Health
was designed to specifically address the needs
is a lack of qualified providers to

reg,lmlens (Arora et
outcomes

20 I 0). This program was developed
with hepatitis C and is now
2

(UNM
fJ'....

I"'''.'' with
treatment

programs to manage a variety

messt:s (Arora et al.). This approach to care

involves professionals from a

disciplines who collaborate and

coordinate recommendations prior to

during hepatitis treatment.

Project
Improving healthcare outcomes can
approach to current gaps in ....

enhanced by applying an
project, the approach

r"f'TU'A

review and critical synthesis

on specific healthcare initiatives related to

hepatitis C. The critique of this

became the foundation for clinical

guideline development and

...... U.HF,"

(Coopey et al., 2006).
with hepatitis C in a shoreline

In an effort to improve care

rural

community in West Michigan and
lTr1nrcn,p'

a

access to HCV treatment were

to

by applying an evidence-based

approach. A five-step model

......r''''''''T

development and included

systematic retrieval of existing

following: clear identification of the

critical appraisal of the evidence; application of results, and evaluation of the
The goal of this project was to ' .......·......r''''''

innovation (Johnston & Fineout-Overholt,
access to HCV treatment by .....

programming that could

",,,,rj

individuals diagnosed with hepatitis

multitude of health
Ultimately, a multidisciplinary,

aa(lre~:;s

treatment clinic was developed

~,-, •• .uu.~U

Chronic Care Model (CCM) was

as

conceptual framework to
management with cohesive and

project. This model seeks to improve

model offers strategies to manage chronic

collaborative partnerships (CCM, 2010).
3

illness by

J.'V ..' ...... " ........

t<>r'y ..t~.rl

on

resources and policies;

on six specific components:

organizations; self-management support;

system design; decision support; and clinical information systems. In "''''''«,!,;'
related needs of patients

1"1 ..",<>1"11"."

C, the chronic care model was fully

but specific clinic

Impleme:nt(~C1

on the components of selt-ITlanlaglement "'""'''''Art
in an .....'''H!-'.

and decision

rr,nnn!?

long-term HCV outcomes.

Background
is

and individuals

remain asymptomatic
difficult to estimate.

C can

of time, making accurate

rates

rates currently exist, reported numbers

not

reflect incarcerated, mentally ill, or homeless populations. HCV exposure results in a
chronic infection in approximately 85% of individuals, and of those, 10-20% will
& Sorvillo, 2008). The presence of chronic

cirrhosis (Wise, Bialek,
increases the

for

"'''-'OJ'''''''

liver transplantation

hepatocellular carcinoma and the subsequent

Wilhardt,

Morreale, 2002). As a health

hepatitis C accounts for 8,000-10,000 deaths per

(Geppert &

Sonnad, &

Cis

transmitted infection (Flamm, 2003)

a

the highest prevalence rates in

of age (Baldo, Baldovin, Trivello, &

Floreani, 2008). Individuals

disadvantaged popUlations are at the

highest risk due to the prevalence

.. "",rr. .." in these populations. The majority of

non-sterile intravenous drug use

persons affected with the HCV

& Vim, 2007). As many as 95%

(IVDU) practices (Paterson, nalCK11nurlO
4

drug users

HCV virology (Geppart & Arora,

20-30%

with mental

U H • ...,"''''

are infected with

Short, 2006). Other populations at risk for the HCV
with

2005);

which is

rates in the genera] population of 1-2 % (Rifai, Moles, &

significantly higher than

54%

It is

the incarcerated where 27-

(Pradhan,

of homeless

nPT"""

(Nyamathi et al.,

and 2.6%

approximate 5.6 million military veterans (Veterans Health Administration [VHA],
2010).
identifYing

'-''''''-''OJ''''

routes of transmission, some
individuals were at increased
to 1991

at

for HCV InlleCl:IOn reqUIres

which are not
of hepatitis C

to risky behaviors. For example,
'-'i\.~JV""UJ,

routine HCV sCfleenmg was initiated

healthcare

exposed to contaminated

risk for

the HCV.

or equipment

risk behaviors

using non-sterile practices; sharing

although
Elements

""".vufrom
Hepatitis C Virus

during blood

blood products.

person; sharing personal hygiene items such as razors
body

knowledge of

at increased

having sex with an infected
tooth brushes; tatltoomg or
drug

~UJ, ,,~,U,-,.

to child (Baldo et

or,
2008).

Treatment

tte1patms C was first ript,"'l'N>ri in 1989 (Choo,

Weiner, Overby,
(RNA)

1989).

is diagnosed

can

blood post-exposure anywhere from 1 180 days after transmission (AI-

Saden, McPartlin, Daly-Gawenda, Connor, & Zelenka, 1999). Symptoms

5

in 10-

include malaise,

acute hepatitis C mIeellorlS

1

",nt"w""",

jaundice, urticaria,

elevated liver pn~7'rn1p", (AI-Saden et at)
C viral genome is not found consistently
explain

infrequent transmission

&

The HCV can be

in more

subclasses (CDC,

contacts (Fried, Shindo,

disease in close or
as one of six

and further classified
of all

Genotype 1 accounts

mrectloJ:lS in the United

is associated with

2002). Genotypes 2

treatment

or semen which

rates to

3 are more frequently

to IVDU (Hamlyn,

2005). While some individuals will spontaneously clear the
that up to

of people will develop chronic HCV which is

virus, it is estimated
asymptomatic

O'f'I1If'T::l

1999).
ViruS,

primary goal ofHCV treatment is sustained
reduction

de(;OIlnm~nsated

cirrhosis, and lastly, reduction ofthe incidence
& Dieterich, 2005). According to

(Santos,

dominant aelemrunmg
from 6
Digestive
ForaH

development of

the progression to hepatic fibrosis, minimization

to more than a

carcinoma of the liver

~'u,~ . . .,....

guidelines,
which can vary

in the course

(Ghany, Strader, Thomas,

2009; National

.""' . ....,"',, Information Clearinghouse [NDDIC], 2010; Woods & Herrera, 2002).
AT""''''''

therapy for hepatitis C involves daily oral ....v,J... "" of ribavirin and
addition, new treatment

a pegylated
with genotype 1,

as triple therapy including

are
interferon,

direct-acting antiviral (DAA) therapy with Boceprevir or Telaprevir. These
protease

have markedly improved sustained viral responses (Ghany, Nelson,
6

Strader, Thomas,

2011). Regardless

treatment

management and monitoring required by the
accountabili ty

provider and considerable

accurate dosing and surveillance. Non-optimal success rates

intensive work

providers are two

Gluud (2010) as to

reason

ug~~esltlorls

only 25%

provided by Brok, Gluud,

LlvV'LI<v

being r'..t1'a....~'rl

are

treatment.

Population of
The community of interest for this project is located along the shoreline of
western Michigan. It is an area characterized by eC()flC)mIIC depression, high
unemployment

populations at risk for

(cru) of a

the Community "''',.,,''''' .....

was 172,188 in 2010 (cru,

population
community at the

and female residents were

the largest cohort is

olds (21.9%) with

With an
community

an

extraordinary challenges

designated
located in rural areas

remaining were of various
With regard to
cohort 5-17 year olds

rate of 17.6%, nearly 12%

designated. It is well

Solovieva ,2005). In

10). Of those living in

of the community residents are I;;;UIc!I;;;(l.LI;;;U beyond high schooL

than
Ir"11rY1Plr'1T

area, the

77% were white, 14% Black, and

racial backgrounds.

(20.7%).

access. According to

setting and all
that those residents living

poverty.
this area are rurally
areas

Spencer, &

accessing healthcare (Goins, Williams,
approximately 1.8 million (1
out of the 140 hospitals
rl..;).:)1.;)lau,_v

Center, 201
7

face

people live in
Michigan,

of them are

. . . P.,..,P.·" 2006 and

2011,

an additional

Lln,'''<'<''1''

lacking confirmatory testing)

hepatitis C

cases (those with

HCV antibody but

to the Michigan ....,"',,, .....,'" Surveillance System,

estimated prevalence of

201

individuals

C for the community

(L. Stegmier, personal communication, July 1

2157 to

estimates as

11)

been infected

interest ranges from
1). These numbers are

reported
Using those same

overall
vU.l"' . . JlU.LJ.VU.:>.

counties north of the community of i"t,,,,,.,,,,,,t have the following
hepatitis

rates of

640 to 760 (L.

County A, 342 to 430;

two of the

personal

communication, July 12,2011).

C

on the
compared to those confirmed cases 1""'~'r."T"''' roughly one third
hepatitis C
when
n ..

..,,".f1,"'..'"

""',.,""',,,"'" the issue of HCV treatment is heightened

been diagnosed.

r-A1,.."t ...,,,... 1",,

are imposed by "V"','vlU'U providers and concerns by primary care

u",\,.,au;~",

of the perceived

appropriate local HCV care.

concern, ~ ..,...."'Vu
local hospital

believed to have

and federally

"''''1''',,"'''

addressing this
from the

to
healthcare agencies.

Barriers to HeV Diagnosis and Treatment Access
and Access to Care
for residents

of healthcare

to

western Michigan that contribute to
care

individuals who

shoreline of

from the HCV in

access to adequate care.
8

community is limited

Goins et al. (2005) describe the perceived barriers to healthcare access among
mral older adults. They depict barriers to healthcare access in three ways: entry,
stmctural, or cultural. The investigators report financial issues as the leading entry barrier
to healthcare access and cite issues with individuals who are uninsured, underinsured, or
lack prescription coverage. Stmctural concerns refer to lack of qualified specialists or
testing facilities in rural communities requiring most residents to travel for specialty care.
For those living in the community of interest, limitations to care are posed by existing
local medical specialists. As a result, people with hepatitis C lack consistency in follow
up. Lastly, cultural practices and norms among ethnic minority populations or groups
may lead to an undemse of services or have additional challenges associated with
language barriers.
Goins et al. (2005) also reported on five common themes that emerged when
assessing access needs, specifically those in mral areas: transportation difficulties;
limited healthcare supply; lack of quality healthcare; social isolation; and financial
constraints. The challenges in accessing adequate healthcare, specifically for individuals
with hepatitis C treatment living in rural areas, was one of the main driving forces in
establishing a dedicated hepatitis C treatment clinic. Because transportation challenges
were the highest reported barrier and were especially aggravated by poor weather and
road conditions, the location of the shoreline clinic intentionally reduces the travel for
these patients. Next, the limited health care supply refers to the lack of qualified
providers practicing in rural communities. Additionally, Goins et al. suggested that when
there is limited availability of diagnostic testing coupled with provider disinterest, illness
management is hindered. The fourth category of barriers describes the social isolation
9

by

adults. This may lead to a lack of understanding of

healthcare

services at the local level. Finally, financial constraints include travel eXt)en15es.
diagnostic testing,
heightened

prescription medications.

concerns are exponentially

individuals are either underinsured or uninsured.

Geppart and

(2005) provide

arguments surrounding the availability

opinion on five clinical-ethical
HCV treatment.

investigators reported

justice, compliance, cost-effectiveness, balance of risk and benefit, and discrimination as
that limit the access to

treatment. As such, these authors

social obligation to

be a professional

nn-th<'"

explore clinical-ethical arguments in

vulnerable populations.

Stigmatization as a Barrier to HeV Treatment
Stigma is a complex social phenomenon which is subjective and variable (Butt,
associated with many chronic infectious diseases such as

has

2008).

is little

leprosy, tuberculosis, and human immunodeficiency virus (HI V) (Butt), yet
exploration into
hepatitis C

social and psychological implications of being diagnosed with

~('('·l'\r,"1.

to Hopwood and Southgate (2003). Discrimination, fear of

transmission, and self-loathing are only a few of
with

with

HCV (Hopwood & Southgate).
avoid healthcare

discrimination,
who have

fail to •.,,,,,v,,,,,, their diagnosis

infectious

UAY'''''u.~...,,,,

fear of ridicule

have strained interpersonal relationships (Paterson et a1., 2007).
through IVDU are especially vulnerable as the

association of drug use and infection is viewed as a self-inflicted

10

"">AUHAV. .

caused

irresponsible behaviors (Paterson et al.). Individuals may

as having

a "dirty disease"
C stigma was examined

an

of 30 studies completed over a 12

year time frame (Butt, 2008). Stigma was most frequently, but not perceived exclusively,
as a negative ....
Moore,

Uti!"'...,\.!

of

and

in a variety

Ina

by

and Bradley (2007), stigma was reported to occur most often in
home setting.
V"~,,'':'''VU''''l':>

suggest that over time,

or family

..,HI.,"A""

can result in

can cause a cascading effect

a

This maybe
vulnerable to discrimination,
& Treloar, 2006). For some, disclosure issues

individuals share their HCV diagnosis with others out
them. This

be followed by

same

sense of

VUJ:';<HIVH

when

to protect

ridiculing or discriminating

against
stigmatization by health prc,reSSIOnal

leGJ;errtent of the

IS

imperative for improved quality of life for per'S0I1S with the HCV. Interventions

('u'.<trt>,-j

toward reversing social perception of infectious diseases can be initiated through changes
in binary thinking, according to

and Treloar (2006). The

accomplished through education on what am)eaJrs to be

~~UAV"''>

believe

consequences

Concepts of" health/illness," "clean/contaminated,"

"well/sick," "good/bad," and "before/after infection" can all be
that

a more

outlook.

in such a

and Treloar further described the

advanced practice nurse (APN) as a qualified professional to cOlirlsel individuals
11

is
by

hepatitis C by first establishing a

relationship. Through individual or

",","·""J'11". the APN can give accurate information on transmission risks,
options,

advocate for

UVL. . . , , ' U

with the

Their

u

........."''''

AHUAU.'l>;'"'

treatment

improved

suggest

for persons with hepatitis C can ultimately reduce their vulnerability to

stigmatization.
In

hepatitis C is an infectious

innocent means, although most

it can be

through

continue to occur by IVDU (CDC,

n"tPf'l'U\"

11).

psychological, social, and emotional responses can occur in those who are
Olagnose:Q with the HCV. Persons with hepatitis C are vulnerable to stigmatization
discrimination by healthcare professionals, family, friends, and co-workers.
QuaJity of

andHCV
indicators are infrequently ..A,.\,y,"t",rI in the

Quality of

In ..... ".r''''n

with

hepatitis C (Zickmund, Ho, Masahiro, Ippolito, & LaBrecque, 2003). Reported studies
focus on treatment

and

but few report interpersonal

challenges faced by those infected (Cotler et
chronic hepatitis C indicate a negative

on health outcomes and reduced quality
The decision to treat

McGuinness,

life
to

between

and rigorous treatment

2000). Published findings on stigma and

C forces

of treatment (medication

negative
and

h"' ... .,i-·'h'"

long-term

effects

gains of eradicating the

(Schackman, Teixeira, Weitzman, Mushlin, & Jacobson, 2008).
treatment

mild flu-like symptoms, nausea, itching,

alopecia (Holcomb, 2008). Cotler et
significantly

headache, irritability,

describe how medication

effects can

the person's ability to function in the work environment or within the
12

home. Financial

may be compromised because of the potential limited capacity

to fulfill employment responsibilities.

treatment can

improved

quality of life ::Sch;acJanan et al.).

Hepatitis C

St'l1"PI"n

decades, Healthy ,-"'''''''''' has identified

For the
detection and treatment

the HCV. Healthy

increase the percentage of people aware
2020). In

objective to

chronic hepatitis C mllectlon (Healthy

this initiative,

attending

et aI., 2011)

Disease week

2020 released

the

Digestive

a one-time birth-cohort screening for

baby boomers, those born in the US between 1946 and 1964 over a ,-""'''' .. period.
Because individuals

hepatitis C typically

diagnosed with

20 years or more.
aware they

the numbers
according to Rein et
Leverence, et

no symptoms,

not be

~~t"h~·~.~·~ a~b!'e-Da~,eo

screening will

HCV and will

(2012).
screemng nralcw:::es

(2009) examined

prImary care

a wide variety of contradictions

providers (PCPs)
scientific national

PCPs reported

as being

and important

(68%) but neglected to obtain necessary information regarding risk behaviors ofIVDU
(54%) or exposure
awareness of

from previous blood

1"1l""P<;I'''Pf'1

study heightened

education

consistencies in national guidelines as
study were supported

(28%).

UH..•..... U.;.u

a qualitative study by

investigators developed a survey to review the
13

to improve care.
et a1. (2001). In
screening practices of

in this
study,
within

the Primary Care

on medically

Network (PRIME Net),

communities. Only 59%

PCPs in the study

about HCV risk factors.

rpr\"rtpr!

This raises concern for underdiagnosis of the HCV

galtek1ee[len;;" who are eSS,ell1Ual

early diagnosis and treatment. In this study,

behaviors

of practice
patients. Participants

and experience with

study practiced in rural,

urban communities.

were found in their attitudes Tr"'J<n'n

No significant

lni1,pr<,PnlPi1

and actual

four provider networks "'''~~''''''P'~!''''f->'

screening practices among

prevention for

As discussions
know that currently no

'"'v..... ,: .......

hepatitis

(CDC, 2011).
individuals with

hepatitis B are

hp?,,,n:n

it is important to
and

for those with

C

known liver disease (Wilkins, Malcolm, Raina, & Schade, 2010).

Populations at Risk
The highest rates

B"IJ...... ~

and those with addictions to

UlvVl1'Vl

C are reported in np,.""n
and/or IV drugs
populations are

same time, individuals in
deemed ineligible

treatment in spite of the fact they

disease. Abou-Saleh and
is daunting because

psychiatric illness
&

most common group
most likely to acquire the

(2008) suggest the dilemma
-~U"'b

2008). At

HCV outcomes

prevalence of hepatitis C arrlong this at-risk
resources available to

population and the limited

Psychiatric Illness
Individuals with
populations who lack

V B. . . . . .AV

illnesses continue to be one

healthcare. This is especially true
14

the most vulnerable
those with hepatitis

C and mental

u .......'a "",..,

that 20-30%

it is

also have

treating
to the

financial burden

with mental

societal obligation to reduce healthcare

access to care.

may

UUA, .... .,.,

attempt to

stigmatization

of access to "..r"f1r'~" and social support, and lack

providers of care,

illness

is of national

inequalities. Healthcare disparities occur when ...".•.,"'....", with mental
navigate numerous barriers

'U"""H~

those who

finances

for services or recommended ph,arrna(~eu
Unfortunately

healthcare ,",,,<.Lu,",u

by the

ill are sometimes

in ignorance and apathy by the healthcare industry. The magnitude
prompted

Institute of lVle:Qlc:me (10M) to

disparities for those with psychiatric

lU"'U.......

Issue

a committee to address healthcare

The committee on Crossing the

chasm: Adaptation to mental health and addictive disorders was developed in part to
"."",.F....." and understand

gap between

who do .."""""n""" healthcare

who could

healthcare

et al., 2007). In this report, the . ."'"I-'UJ.h'.... between

these two groups is described. With this understanding, the committee was charged with
......,J:\.Ul'f::,

recommendations to reduce these disparities. The orc,oo:seo framework to

improve healthcare delivery was focused on six important criteria: natlerLt-c:en1ten!O
timely, and efficiency (Pincus et al.).

effectiveness, equity,

Treatment and Psychiatric Inness
The

Institutes

with psychiatric

suggest that
on a cruie-[)V-(

treatment

basis (Mistler et

considered for
2006)

UI..'I..'(lU;:)1..'

profound risks associated with treatment. Psychiatric co-morbidities include a
diagnosis

depression, ",,,,..cnn

disorders,
15

disorders, anxiety, post-

traumatic stress

or other mental

,,,,,,rflr'r

Linden, 2005). Neuropsychiatric side
(Strinko,

PTT'>!'T'"

are well known with interferon

Hoffman, 2004). One third of persons receiving

Bisceglie,

treatment will exhibit neuropsychiatric side
illness can

& Van

Rifai,

pH-""t",

and individuals

devastating C0I1Se'Ql

& Gabriel, 2003).

the most common reported neuropsychiatric
emotional lability, irritability, anger,
disorientation" (Silverman, Kim,

effect

QQ]:es~Sloln.

by ZicknlUnd et al. (2006), physical, mental,

study, physical side

with "panic

a cross sectional study

social complaints of patients undergoing

by 80%

psychiatric

. H U ,........

unrecognized

effects (Crone & Gabriel).
of ,nTprTprr." usually exclude individuals with

on the

based on physician reports of depression and not on a professional

psychiatric assessment (Mistler et

2006). In

in a study by Alfandre, Gardenier,

Federman, and McGinn (2009), over 75% of persons with documented
were medically eligible for

tre~ltrnent,

illness was reported as a reason why
Individuals in

to successful

did not

and modes

C, who

therapy initiated. Psychiatric

to initiate treatment was so

population may have lower levels of health

understanding of the
insurance, low

's

the participants while 38% rpnnrt.>fi

depressive feelings. Suicide and death have been reported in persons

Research

anxiety,

practice needs for providers. In Zickmund et
were

untreated psychiatric

IS

hypomania and uu.;,,,,,,, confusion and

Freudenreich, 2010, p. 2).

treatment helped to

-0,,----'0 with mental

and lack

transmission (Alfandre et al.). Lack of

of literacy, and limited access to
treatment (Gardenier, Neushotz,
16

serve as further

n<>TTlP-r"

O'Connor-Moore, 2007). Crone

Gabriel (2003) reported that
chronic

C
",n~l ..,,·n

of life .u...."',..v,'''' are impaired for persons

are especially significant for

with

Social

interpersonal relationships, and Sm;lOeC()llCm

constraints in

with psychiatric illnesses lead to non-compliance with appointments, testing,
and psychiatric medication which contribute to further ineligibility

In

Weiss

Morgello (2009)

the most common

effect

HCV treatment

worsening symptoms.

specialty

illness and the HCV. Depression was
....""."'uu'vu.

However, the majority of

providers acknowledged that treatment needed to
because

results

",,,..-uP,,

providers who service individuals with

HCV treatment.

this study, 65%

than 20%
'''''.IT'''''''T<'

the

with psychiatric UH1.'-''''''

achieved a 20-60% sustained viral response from treatment which is the
treatment success for DeI'SOIlS without

The investigators concluded that

stabilization of psychiatric ~.u_~"~ is incredibly important prior to
in order to reduce the neuropsychiatric

systematic reviews

2009

Mistler et al. report, concluded that

<Yln-""",,,,·,,,,,"

2006

explored

which investigated 13 studies. Both

that patients with psychiatric illnesses are commonly

excluded from clinical research on hepatitis C.

low drop-out

(2009) completed systematic reviews

individuals with mental illness.

research studies as compared to

therapy

effects (Weiss & Morgel1o).

et al. (2006) and Quelhas and
examining HCV treatment

starting

of the

the

majority of individuals completed therapy

adhered to treatment guidelines,

psychiatric management

included

Ide-ettects when

close monitoring was used. The bulk ofthe

reviewed were from small studies and overall conclusions support
17

outcomes in

treating patients with mental illness and hepatitis C.

suggests that controversy and

are common over whether or not ...",......u illness should be an absolute
for HCV treatment.

HeV Treatment and Substance Abuse
Historically, substance abusers or
deemed
2009).

addicted to either alcohol or

for HCV treatment based on

may include lack

belletlts. poor compliance,

factors (lohn-Bastiste et aI.,

readiness, perceptions that harms of treatment outweigh
treating the

health concerns. (lohn-Bastiste et

has low

when compared to other

Because IVDU '"'''', ...... ,''' as the

cr ..""<>t",,,,t

new virus (Armstrong et aI., 2006), new treatment

m

considered for these ,,u-, •.,'" populations.
because

are greater numbers

challenges

risk

need to be
further

IVDU among individuals who are

for HIV,

which accelerates the progression ofHCV-related disease (Bica et aI., 2001). In fact,
the HCVas

authors

primary cause

death

in this HIV-seropositive population. One strategy reported in the literature has been a
comprehensive u,","'",,,,", eXlch,mg;e program implemented in New York that has
substantially

(Birkhead et

that

2007).

been closely ".U\u.....u as it pertains to epidemiological
histological

m(]tlc~ltOI:S

associated with

Hepatitis C infection is foood

nearly 40% of . . ."' •• '-'....., with alcoholic liver disease and

leads to rapid

in patients admitting to ingesting >40gms per day

veJ(mITLent of

alcohol (Degos, 1999).

,,"'UU.,'" there is an impaired respOItlse to interferon in individuals who use alcohol,

greater morbidity and mortality contribute to poor outcomes (Blackard,
18

Bordoni,

Shennan, &

....."u~.n!'"

2004).

a result, there is an extraordinary

for

programming focused primarily on individuals with n",,,'n'>I
UU\..u ... 'k... U

to

c.

alcohol that also

Treatment Guidelines and a Multidisciplinary Approach
et

(2009,2011) authored an pvtp""""P

diagnosis and treatment of hepatitis C.

published guidelines were approved by
'-' •..,"'.....,,~.., (AASLD), the Infectious Lfl;::'I;,;Q.;::'\;:;;::'

American Association for the Study
America,

the

on guidelines for

......'v",....'"

>JV'Io#l .... y

of Gastroenterology.

clearly

states that "interferon and ribavirin can be safely administered provided there is
comprehensive Df{:tre~atrnellt psychiatric assessment, a
and

benefit analysis is conducted,

are provisions for on-going follow up of

symptoms during
1362).

antiviral therapy by a multidisciplinary team" (Ghany et al.,

National
be

persons with substance abuse and/or mental

Institutes of Health suggests

(Mistler et aI., 2006). The complexity of
individuals with hepatitis C and
variety

of a multidisciplinary

The

C was presented

approach in
(2011) showing

nrrn,p'rl

increased quality-adjusted

input

co-morbidities may

at

annual r>r....

compliance, lower

LlJLJlJ

reSDOIlse. and

years (Garcyia-Retorillo, 2011).

Relevance for Nursing
registered nurses (RNs) playa

Advanced practice nurses (APNs)
In

care

individuals with hepatitis C and are

uv.·..>"u

to

an even rrr"·,,,t,,·r role

future (Olson & Jacobson, 2011). Development and implementation
19

role

most models

care for individuals with hepatitis C involve
articles

been published on the
individuals with

1999;

nurses in

",,,,,,,"'''-'.C'

Gardenier et al., 2007;

roles in the management
Cheng, 2010;

HCV (Ahem,
2006;

Vu, &

nurse as a central caregiver.

& Ghalib,

2007; Ford

2007;

& Timmins, 2009, 2010; Johnson & Holman-Speight,

2005; Leone, 2002, Lewis, Allen, & Warr, 2010; Olson & Jacobson, 2011; Poll, 2007,
Robathan, & Vyas, 2008; and Van Zandt, D'Lugoff, &

2009;

However, of the

on benefits

lead

to study specific improvements in care outcomes managed
Ehsani et aI., 2006;

,-,AV""UU

(2006) studied

APNs (Ahem,
2008). Ahem

quality of life nOlcators and treatment

outcomes

physicians. While there were marginal

indicators by provider groups, nurse

of

provided as equal care when compared to DmrSlC:lans.
studied

only

Timmins, 2009, 2010; and Shutt et

outcomes between nurse practitioners
differences in

2002).

most common side effect reported

overall

and Timmins (2009, 2010)

HCV treatment and whether patients

were satisfied with the care received by a nurse specialist practice. Fatigue, sleep
lfo;anc:es. and
high satisfaction

loss were the

reported side

mana:gernel1t of complaints by
stakeholders were

study completed by
nurses playa central role in
crucial for education, side

treatment. Those ''''''''''''''il''',", agreed
UA""""",5"'.U"''',

In a qualitative
to
nurses were

counseling, and treatment compliance
et a1. (2008) conducted a retrospective case

when managing HCV treatment. Lastly,
looking at

and patients rated

the addition of a clinical nurse specialist (CNS) impacted HCV
20

and treatment between 2003 and 2006 and
provided in the

years (1999-2003).
treatment doubled

it to care

f',UlnnlOl

reported that the rates of
the

with

CNS with improved

follow up including an increased number of ess.ell'nalliver biopsies performed.
findings,

United l\.lngclorn passed mandatory requirements that CNSs

involved

treating HCV (Shutt et al.).

The remaining literature relative to nursing and HCV treatment focused on
H.U",",UV1L'U):!.

at

fullest

By definition,

are

registered nurses educated to function autonomously and collaboratively in an advanced
and ext,en(led clinical role"

'-''',",HI;;',

2010, p.6). According to several investigators,

nurses can fiU

to

care

providing

management and support services (Clark & Ghalib, 1999; Johnson & Holman-Speight,
2005; Van Zandt et al. 2002).
by nurses for
et al.).

model

the Wald Model is community-based care

an

who are economically

care

pr",p'n/Pn

(Van

to accessing care

on identifYing the

these barriers by evaluating community resources, improving health education,
advocating

patients,

care working
access to

h""r·~ ..."

involving families. Conclusions

model "'U~~l"."''''' that

collaboration with a HCV treatment centers could

by reducing the

of side

lan:lgemeltlt with

follow

up.
Poll (2007, 2009)
prevention, diagnosis,
nurses

the important role of the community nurse in the
management of individuals with

the lead role in educating on transmission
21

hPr'lOlT"T,

of the

this study,
and identifYing

persons at highest

in diagnosing

Improved scr'ee1nmig protocols
with the HCV who

,1".,1"

crrl'..

numbers

""P7',;>£",,""

eligible

treatment, a clinical nurse specialist manages medication dosages and side

effects, laboratory monitoring,
between SU(~CeSSI

otherwise remained undiagnosed. If

supportive care for patients
completion ofHCV treatment and

effect management was clarified in a study by

(2002). Side "' ...... "" . ." include muscle

flu-like symptoms, fatigue, sleeplessness, loss
L"'""'.AUV."",",

(Leone).

U", ... a.l.l"'"

libido, nutrition concerns,

of the profound side ",1"1".>('1"" compliance with treatment

regimens is difficult when treatment courses
remaining studies describe

from 24-48

role of nurses in managing hepatitis C in

difficult populations (Fahey, 2007; Ford & Cheong-Lee, 2007;

et

et aI., 2010). A case study reported by Gardenier et al. described
medical/psychiatric

2007;
use ofa

with nurse practitioners. Historically,

individuals with active substance use and psychiatric comorbidities have been ineligible
HCV treatment.
'U~"Uf"'"

suggest

study sought to remove those restrictions on eligibility.
barriers to HCV

use of case management can

treatment. Similarly, a model of care involving the addition of a
nurse specialist on a drug and alcohol team was

by

hepatitis clinical
(2007).

model, education and risk assessment care occurred in conjunction with drug and alcohol
support groups. This model also includes nurses performing basic diagnostic testing

Ford and ......l l.... VIJLlo'.-l...,"'''' (2007) reiterated the need
central

hepatology nurses to have a

establishment of the Canadian Association

managing HCV treatment.
22

of Hepatology Nurses (CAHN) in
..... "','.........,J

the

'-'H,"-VA,U":'

H";U!"'!",HJ'!", n,:lt'I"ntc

has improved

ability

nurses to network and

challenges of managing HCV patients. Authors suggest

who have

health problems and hepatitis C can be

especially difficult to manage (Lewis et

2010). In fact, persons with mental illness

have the highest rates

hepatitis C infection yet are least likely to access care. To

Improve

health outcomes in two United

development and implementation

"'>.ULi".UVUL

communities,

HCV protocols were initiated.

clinical nurse specialist improved care

involvement

this especially at-risk population by

case mana:gernellt monitoring.
In sum, APNs exist in multiple
healthcare

V1V'.I. .... .;>.;>LVUUl

and nurses are the most consistent

in contact with patients. They are in an ideal position to advocate

for improved access to HCV treatment and monitoring. Nurses can improve long-term
health outcomes by reducing the health disparities among those most vulnerable. By
F,YJ,"""'","""

or protocols

HCV care, APNs are a

In

collaboration of care, education, counseling and support, and advocating for improved
HCV progranlIning.
Summary
......("'v".....

state,
C treatment is

important factors pertaining to

reviewed

dilemma.

local

to

and involves

complexity of hepatitis
care.

the majority of individuals unaware

includes inadequate HCV screening
of their hepatitis C diagnosis. For

magnitude of

who

been diagnosed, there are limited

numbers of qualified healthcare professionals and treatment programs available in the
23

community
criteria

interest.

further complicate the
treatment.

to

morbidities continue to be

patients face rigorous eligibility

illnesses, substance
for individuals

"'''''''A'-A'''F.

inadequate healthcare coverage, lack of

social

for those

and co-

HCY treatment. Additionally,
support,

in surrounding rural areas are

lack of

to HCY treatment.

The dilemma of hepatitis C is on the rise and expected to be at its
decade.

quandary will

impact

heightened if healthcare providers adopt the

birth-cohort

and

are

charged with finding solutions to the challenges associated with screening

treatment

of hepatitis

boomers.

It is imperative

innovative approaches to HCY care address

limited access issues.
In response to
hepatitis C

dilemma

local,

and national healthcare agencies, a

was proposed and initiated as a doctor of nursing practice (DNP)

project to improve the care for individuals with

C

the

of westem

Michigan. In order to provide an evidence-based approach to this project, the next
VA . . . . . . . .'VA

will present current

outcomes

literature on models of care to improve health

individuals

24

2
LITERATURE REVIEW

of this
for HCV

is to review the

to models of care

community-based clinics. This review will encompass common barriers to

treatment as they relate to models

care identified in

literature. To thoroughly

explore current literature focusing on models of care for individual with
following

y<nuv",,,,,",,,,

the

were reviewed: CINAHL; Cochrane Reviews; Medline; PubMed;

and PsycINFO.

words or phrases

treatment; multidisciplinary; integrated
treatment; collaboration; and

this

included hepatitis C; approach to

nursing; nurse practitioner;
In addition,

to

lists of all

literature were reviewed for potential inclusion.
The absence of randomized controlled studies or comparative
of care was a notable
(Ho et

2008;

m

two study
in

et aI., 2006).

aeI1ce;-D,lsea care for
treatment models, an

review and

Due to the

the

,>Mc&'t'n'<"\"

ofHCV

was made to

all

of consensus on HCV
it",r"t,,..,, pertaining to

current HCV models of care. To adequately develop a comprehensive treatment
for persons with hepatitis
L~ULvU<"

investigating existing programs and

that contributed to successful treatment was deemed

25

those
ultimate

goal of this

was to allow the literature to guide and support what type
would contribute the

literature

of the early stage

outcomes.

included

that were

and consensus

as

well as those reporting expert opinion.
Three approaches to HCV care were identified in databases including
multidisciplinary, integrated,
reviewed

compared to obtain insight into the challenges associated with treating

individuals with
....".JIF,''',

The ,",.n."0~,u ... literature was

care

literature reviewed was compared by

"""",,,,1"11",<-

methods, theoretical

and participants, inclusion and

TT"gTrlP'UTr'TV

exclusion criteria, variables, scales and statistical
limitations and implications

study, and lastly,

clinical practice.

Multidisciplinary Models
For the purpose of this review multidisciplinary refers to healthcare providers
from different professions who work together to coUaboratively provide diagnoses,
assessments

treatment, within their scope

and areas

competence.

contrast, interdisciplinary refers to the blending of two or more academic, scientific, or
artistic disciplines (Merriam-Webster, 201

Thus, when describing models

care for

hepatitis C treatment, multidisciplinary care in this project constitutes the collaboration of
health

including

care providers, infectious

physicians,

hepatologist/gastroenterologists, nurse practitioners, pharmacists, addiction
psychiatric

and social workers. This model was selected to

<".tf, ..

"",,:o common

Because most patients with hepatitis C are

complexities seen in patients with hepatitis

from high-risk populations (C. Everett Koop Institute, 2012),
26

encounter significant

Instituting a multidisciplinary approach to HCV treatment ~. . .., •.., .....

m
patients

navigating barriers and allows healthcare professionals to provide an expert

focus within their discipline.
specific use or recommendations for mUltidisciplinary
programming in

treatment of hepatitis C (Arora et aI., 2011; Dolder et al. 2002;

et aI., 2007; Grebley et al., 2010; Guadagnino et aI., 2007; Koff, 2001; Nazareth,
Piercey,

& Cheng, 2008;

Schoenfeld,2002;
specifically

2008;

Gebremariam, &

Thiel, Anantharaju, & Creech, 2003). Four of the
on

of

articles

studies employing a multidisciplinary

!:lnr\rl"\<>l"n

to H CV treatment.
Arora et

(2011) conducted a prospective cohort study comparing the outcomes

hepatitis C treatment with individuals who were under treatment

Extension

for Community Health Outcomes (ECHO) treatment protocols in a university
treated by primary care providers
included

21 rural

sites.

treatment sites

teleconferencing allowing

in New Mexico.

a multidisciplinary team to collaborate with local
provide treatment. Of

care

were

(58.2%) in the

to

146 individuals treated for hepatitis C at the University

Mexico (UNM) HCV clinic, 84 (57.5%) achieved sustained viral
the 1

with

sites. Interestingly, reported rates of serious

a multidisciplinary approach

27

effects
This study

in the UNM site (13.7%) compared to (6.9%)

suggests benefits in treating individuals with hepatitis C

compared to

typically underserved

health technology.

of

""""'"6."""" et al. (2007) designed an observational, prospective study to explore

the

of a multidisciplinary approach in six infectious disease centers in

collaboration with 11 Italian drug detoxification units (DDUs).

partici pants

underwent psychological ."''''Ul/; to identifY underlying mental

Of the 53 subjects

studied, 54.7% achieved ., ....,.UU,l"'''' viral response. Team members were available for pretreatment counseling and during treatment evaluations and management. Weekly
consultation at

continuous ,.,..,,,.nn,n·,

DDU allowed

and encouragement from the

team members. In this particular setting, all team members had an active role

assisting

patients. The relatively small sample size and type of drug treatment programming were
recognized as limitations of this study.
Grebley et al. (2007, 2010)

most of their work on the

support

groups for individuals with hepatitis C receiving directly observed HCV therapy. In this
study, weekly support groups served as a ......

'vu.I.UU .... H

for patients to

social support. In the 2007 prospective study, 80 subjects were referred to

education and
support

group over a period of 80 weeks. Of those, 18 patients who were illicit drug users
enrolled in the study and

HCV treatment. In total, 8 achieved end of treatment

reSPOltlSe (HCV RNA <50mIIlU) despite some patients having to discontinue early.
11U.I"/;"

support the feasibility of HCV treatment

by integrating a multidisciplinary approach and a
this study is limited by the small study
The
extension of

IVDU

support

of

and lack of clarity in ,." ......... rt,

0 study by Grebley et al.

a

approach and was an

2007 study. In total, over a 3-year period (2005-2008), 204 individuals

were referred to the weekly support group within the multidisciplinary program. Of the
28

109

for treatnlerlt, 57 ofthose referred received treatment suc:ces;sru

was a significant association between

A ... ...,,"..., ...

at the first four weeks of the support

group and the """'.A...,.. ...., undergoing treatment for .,,'''.'''TlIT,
success in

There

these studies report

individuals with current or former IVDU and hepatitis C by

integrating a multidisciplinary care approach and a weekly support group.
study by Dolder et al. (2002) reported outcomes

veterans

a San Diego

Veterans Healthcare system. Their study examined access and cost ofHCV treatment by
utilizing either a high intensity HCV treatment model involving a multidisciplinary team
or a low

(traditional) approach where

reterred, and

cases. The high intensity approach was found to treat a greater

number of veterans more

versus that of the low intensity model.

found the

treatment model totaled $33,318 compared to

$38,082 for the low-intensity model. This study was one
burden of hepatitis

cost

The authors described the cost

few to focus on

liver transplantation as

exceealmg $240,000 with an additional cost burden of $23,488 per
by

follow up care. Updated

liver transplantation suggest a total cost

financial

for

Foundation (ALF, 2007) for
$300,000 for hospitalization, physician fees,

pre/post-operative testing. This study further describes the importance of
pretreatment education and counseling as a means to increase completion rates.
Implementing a multidisciplinary (high intensity) program increased the numbers of
veterans who were able to successfully complete therapy. Conclusions reported in this
study were based primarily on expert panel opinion
rates were

on

seen

clinical trials.
29

estimated

completion

cornerstone of

a multidisciplinary approach is the participation

of professionals from a """'PT" of specialty practices. To
components of the

model, studies were reviewed to compare

me,Qlc:al specialty of the lead provider in the care of patients with
"'lv1Ull.;)

were vV1,'''''',!''''

the

provider

2007; Grebley et aI., 2010; Guadagnino et
specialists were considered
2001;

three

C. Infectious

"LULH"'''

(Grebley et

2007), while hepatologist or liver

lead provider in another

et al., 2008). Two

studies (Dolder et al., 2002;

referred to

in both infectious

disease and hepatology as the primary leader of the healthcare team (Arora et al.;
2008). Additionally, three
multidisciplinary

examined the benefits of the addiction specialists
for individuals undergoing HCV treatment

former history of IVDU (Grebley et al., 2007; Grebley et

a current or

201 0; Guadagnino et aI.,

2007).
In most of the literature regarding the use
practitioners/nurses played a central role
(2008) and Pozza (2008)

a multidisciplinary

nurse

coordinating HCV therapy. Nazareth et
(NP)

the role of the nurse

managmg

patients undergoing HCV treatment with ancillary collaborative ... <lr't",,,, ..,,,
professional disciplines. Nazareth et al. (2008) introduced
of Care in an Australian study. This

other
...,..'..". Model

describes how trained

nurse

practitioners provide increased opportunities for '"u ... "''',<-'''' management, assess
Iaclcors associated with the HCV,

mcrease

individuals could be screened or treated for hepatitis.
benefits of the nurse practitioner in treating the
30

of

in which
(2008) reported specific

a study examining clinical

evaluation and management in co-infected (HIVIHCV) populations. In
education

support in

side

patients can be successfully 1'r",,,,1'P'rI

study, NPs

management.

a multidisciplinary approach and

collaborative efforts between physicians, NPs, and other health disciplines
~..,....",

sum, the literature

to the use of a multidisciplinary

approach to hepatitis C treatment suggested increased rates of treatment success.
Collaboration among professionals from a variety
assessment of

with an

health disciplines ensures

rnrlrn'" .....

chance of "",1"P""1'" completing

treatment. Limitations of this review include the lack of controlled studies describing a
multidisciplinary approach to hepatitis C treatment. This includes the inability to
generalize

use

a multidisciplinary approach in open access settings as most of the

literature LV""':>'-'U on vulnerable populations challenged with a specific treatment barrier.

Integrated

Models

The term ......1'''',-...'''1'''',;

1S "'''',un,,,,,

as "combining or coordinating "",""..

",'t",

as to provide a harmonious, interrelated whole" (Dictionary, 2011). This type of care
model for the HCV attempts to assure collaboration of services for vulnerable
mt~egratea

populations. In

models of care for

increased coordination of

fragmentation, improved
care. Incorporating the professional services
for both

multidisciplinary model

integrated approach

treatment reduced

a variety of health disciplines was similar

care and integrated care models. Yet, the

the literature review directed care more often to the patient's

specific barrier to successful treatment.
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Eleven articles were reviewed involving integrated care strategies in HCV
treatment. Four reports

""'F>F>"'':;

an integrated approach to HCV treatment for individuals

with current or fonner illicit drug use (Birkhead et
et

2009;

2007). One study

2007; Fahey, 2007; John-Baptiste
the benefits of an integrated approach

for psychiatric illnesses and treating hepatitis C (Knott, et aI., 2006), and two studies
described the use of an integrated approach with persons who were co-infected with
HCVIHIV (Palepu, et aI., 2006;
.. "',...·"' ...rI

et

Clayton, & Chang, 2003) .

2006; Hill, Butt, Alvarez,

Krajden 2008; Ho et ai., 2008)

explored the advantages of an integrated care model. Two articles discussed

benefits

of integrated care in gerlenl1l2:au'OI and not within "''''~'vu .• v vulnerable popUlations
(Garrard et al.; Hill et

and the third """""u,,,,,.... care

veterans

or without

psychiatric illness or substance abuse (Ho et aI.).
they exist, integrated care models support collaboration among professionals
in addiction treatment,

evaluation

and infectious u,,,,v,,,,,,,,

Successful HCV treatment is often dependent on comprehensive pre-therapy evaluation
and treatment of conditions that pose a risk to therapy outcomes. Historically most
individuals with 'u~,..".u illness or substance abuse were deemed ineligible

HCV

treatment. With infonned support from integrated team members, some practices are
conditions are no
(Birkhead et aI., 2007). To support these
Study

Liver

treatment would not

an absolute contraindication for treatment
'"''''''''''F>''''

(AASLD) recommended

American Association for the
treatment guidelines so that

automatically withheld from persons with current drug use

treatment should be considered on a one-to-one basis (Ghany et al., 2009).
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additional considerations

evaluating illicit drug users for HCV treatment

include the risk of continued transmission should they not be treated,

risk ofre-

infection once 1"r",,,1''''/"1 and compliance concerns regarding contraception requirements
while on treatment.
of the eleven
approach

reviewed the incorporation

HCV treatment as a focus (Hill et

an integrated care

2008; John-Baptiste et

2009;

Columbia; 'or<mtc), Ontario;

et aI., 2006). These studies were done in Vancouver,

and Minneapolis, Minnesota, respectively. Both Canadian studies used an integrated
approach to HCV treatment in a community-setting; the
-1..I"""vU

study was done in a

Veterans Administration (VA) facility.

Hill et a1. (2008) examined the benefits of referring patients with
local community-based program for educational programming and treatment.
study, in just over a four-year period, 1
Seventy-four percent of those r",1',o.rr,>£1
treatment. Of

sustained response.

this

individuals were sent for UAvun,,'LU evaluation.

r'>l"'plU~'n

education but only 26% were deemed

363 initiated treatment

individuals. Sustained viral response was achieved
individuals sent

C to a

outcomes v v •• v v . v .... on 205

61%. In sum, of the original 1795

evaluation, only 126 completed HCV treatment and achieved
nUIPH.'r

this study . . .,..'''',..,'.£1 success in integrating partnership

between physicians and nurses leading to an increased number of people served.
John-Baptiste et a1. (2009) completed a rph''''C'''''''l'''tnlP study looking at HCV
treatments within Ontario Addiction Treatment "'-'VA,"""

(OATC)

model involving hepatitis nurses, psychologists, an infectious
primary care providers. Pretreatment screening was performed
33

an integrated
specialist,
nurses over a

of

aef:mt::a eligible
u ...,'v"",.....

treatment were seen for at least one consultation by the

physician prior to starting therapy. Of the 4000 individuals seen at the

OATes during the study period of November 2002 and January 2006, it is estimated that
50% of those had
rp.I',p.",,,rI

Of the

2000 with

HeV, only 109 «6%)

at least one interferon injection. Study outcomes concluded that HeV treatment

can co-exist with addiction treatment with the support of additional specialty practice
partners.
remaining research study used an integrated approach to HeV treatment
the core elements of routine screening for psychiatric andlor substance use
a psychiatric clinical nurse specialist (peNS) within the

the

veteran's facility (Knott et

2006). Psychiatric screening tools were used to initially

evaluate participants who were eventually divided into four £''''1''''n,~ .... ,,,,, patients without

"'. . . . . .v...u,"". who saw a peNS (alone or

parlenLs with

positive

additional to a mental health provider outside the clinic); patients who

positive

saw only an outside
screening but

health

".,.T"lJU·'"

screening, 149 had at least one positive screen. Of those who started treatment, 34 were
in the peNS group, 8 were treated by UA,",'''~A health
treatment
of this study focuses on

outside the clinic,

6

they opted not to accept mental health """"'''1(',>" The importance
integration of psychiatric services within the hepatitis clinic.

seen, mental health Wfles:ses and

;:'U'-';:'",:;Ul\.,,,",

use are

to

treatment and an integrated care model can support early interventions
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Hev
those at risk.

The remaining literature regarding the use of ....1",P£H">1""'./i models of care for
treatment discussed

with

Garrard et al. (2006) 1""'"",1"\""-,,,,, barriers

and
fragmented

use

integrated care included

systems; financial disincentives when psychiatric

obtained outside of the treatment program; and

on individual health barriers

may be over looked. In contrast, Stringari-Murray et al. (2003)

while other

suggested benefits in an integrated approach for individuals
HIV.

are

study described HeV

HIVI AIDS specialty

from both HCV and

incorporated into an already established

in Marin County, California. Recognizing that persons at

for HCVIHIV are also at risk for acquiring other infectious diseases, true integrative
services included appropriate ",,,.,,vJ'UAJ.F, examinations.
way to

v .....,uu."""

numbers

servIces was seen as a

healthcare resources. This study inconsistently described participant

these

concerns

certain barriers such as alcohol and

study validity. However,

use remained high and a significant number

patients reported psychiatric illness. Additional barriers requiring further work up
included

of stable

insurance, and the

comorbidities.

Developing partnerships with mental health services, establishing a case-management
program,

most importantly, cultivating the

of the nurse ......,"ht'l"\n

with

guidelines were suggestions posed by the authors.
In sum, the literature reviewed on integrated models
to

treatment availability

discrepancies in

with hepatitis

However,

literature that support fragmentation of care with

This model focuses on integrating services

HCV
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approach

care support

"'V~''''VUUAr..

are
type of model.

treatment

locations

individuals are already receiving services for substance use or in community-care
settings.

consistent benefit

management of

Shared

nurse practitioners or clinical nurse specialists in the

treatment was highlighted.

Models
articles were reviewed involving a shared care model approach to

treatment (Belfiori et al., 2009; Ewart,
&

UI ......:>l\J..

Joyner & Safe, 2004;

2006; kOiltorm

Tait et aI.,

studies were research studies that utilized

specifically

of the

shared care model in treating hepatitis C

et aI., 2009; Kontorini et al., 2003; Tait et
conducted outside the

10).

Gordon,

2010).

Italy, Australia,

studies were
the

Kingdom

respectively.
The

studies examine the benefits of involving

care models in

mUltiple disciplines

manag;ement of

insights to the advantages of "sharing"
treatment

"E'>'''U"U>J

for patients and

treatment.
work load when considering

intensive

time-intensive monitoring

providers. By sharing responsibilities, increasing the availability
protocols and improving

provide

appropriate screening

mcaLllageInelt1t of side effects, increased compliance rates were

noted.
Belfiori et

in Italy in a drug maintenance program.

(2009) studied 52

This mUHl-cernre pf()Spectlve observational study was completed between 2003 and
2006. Of the 52 individuals

met inclusion criteria, 45 completed treatment

achieved a sustained response.
specialists

of

program included addiction specialists,

infectious disease, and psychiatrists. Frequent monitoring by members
36

the team allowed for early interventions and treatment modifications. This study
suggested hepatitis C treatment success when treating IVDUs who were on
methadonelbuprenorphine was possible.
The shared care model reported in
2003) varied slightly

prospective

study (Kontorinis et

that surveillance monitoring was shared with the general

practitioner. This approach included hepatologists, nurses, 1"11'11.,,<=11"'<' care providers,
.:IV"."","'.. .:IL,",

from

disciplines

offered psychiatric support. Hepatitis C treatment

was initiated by the hepatology staff and followed with routine monitoring of blood work
and

the 81 patients trp<=ITP'i'! 54 had

visits

failed attempts of HCV treatment. In this study. 40% of patients achieved
sustained viral reSpOlrlSe and of those, 24% were genotype 1

58% were genotype

By using a shared care model for H CV treatment between np""pr<=l
practitioners,
increased

and nurse

authors reported treatment regimen compliance rates of 98% and
confidence.

last research study reviewed

C treatment.

the shared care

<u....'rl"\<'t>h

(Tait et

0) to

Networks (MCN) as a means to enhance access

HCV treatment looked at Managed
to

f't1T',I'\""p1'Q

MCN added new pathways

referrals which included

non-medical referral from addiction services, prisons, and outreach nurse-led
a

Using this model, the access to HCV
61

to 82.4%.

et

/L_"",., ..

are

these

in-network collaboration significantly increases access
difficult to

locations.
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period, in this study, rose from
with previous reports that
individuals

traditionally

Two articles on a shared care model approach to HCY services addressed
benefits with an increased role

practice nurse in the

management of hepatitis C

2004; Hamilton et aI., 2006).

showcase the value of nurse
surveillance of appropriate

"'1-'''''''''''".''"'

patient education, side effect mana:gernellt

'UUVLI..t>V>

"....' "... '"''', and oo:se-a01ustmelrlts.

within their scope

liver specialists,
primary care providers, nurse

psychiatric and addiction ':>IJ"''''''U':>

were

treatment.

able to appropriately

In sum, the literature reviewed on the shared care model as an approach to
hepatitis C treatment focused on

access to treatment when limited "1-''-,'''''',,1>

are available. Essentially, the model uses a multidisciplinary approach, often
a lead nurse practitioner in collaboration

with

partners in other disciplines. In
traditional barriers

MCNs offered added benefits to "''''"''-'''':>H11:', care
extended wait times.

multidisciplinary, integrated,

Three models of care

shared care. All three addressed common barriers to treatment and proposed to improve
access to HCY treatment. Psychiatric and substance use challenged the healthcare
system to improve care delivery

""'l""""'~"

the highest prevalence
ineligible for treatment. National
supporting efforts

In

studies, these at-risk populations

continue to
1:',"","''''''''''''''

now

the largest group ael:enntrlea as
and encourage a ""H''''HI';''''

treatment evaluation. By instituting .....'-',0..<1
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which promote collaboration ...."'1''''''',." specialties and primary care, patients with
have a significantly greater chance at completing treatment.

Scholarly Project
In order to

the care

individuals

the shoreline of western Michigan, a
gained
hepatitis C

project was initiated by incorporating

review
focused on

C in a community along

design and
cre:aSllng access and

ad(lIe~;SmlQ

perceived

,",'3?'1"''''''C'

to

treatment. Evaluating community support and perceived need for improved access to
first step
literature

this project. Knowledge

elOom.em and implementation

the

from

current

community-based,

multidisciplinary treatment program.
In this

healthcare disparities for vulnerable populations with hepatitis C

identified many biopsychosocial challenges. The magnitude ofHCV as a healthcare
UH'''"'''!.'''''' was highlighted and peak prevalence was forecasted this decade.

programming, using a multidisciplinary
individuals with HCV.
translate research
based

was

project used the principles of implementation science to

clinical practice by developing and implementing an

to improved health perceptions for people with hepatitis
barriers to

for

doing so,

treatment were addressed and comprehensive HCV care was

implemented in a cohesive, community model.
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CHAPTER 3
CONCEPTUAL FRAMEWORK

The conceptual framework

the Chronic Care Model (CCM) was used to further

understand the complexities of
Ut:l;t:::s:sary

Cand

programmmg

to adequately care for individuals with hepatitis C.

based initiative aimed at

,",UL.,",U,'F.

CCM is an evidence-

the gap between scientific underpinnings and quality

patient care (Oprea, Braunack-Mayer,

Stocks, 2009). The

has been

by individuals who seek to improve chronic illness management with cohesive and
collaborative partnerships between patients and providers. Although the CCM was
developed

use

applied to a

care, it

and targeted populations (CCM, 2010).
components

CCM focuses interventions on

management support; delivery """"Pfrl

U'v.H,""U.

systems. Each

smlte~~leS

mam

healthcare organizations; self-

care: community resources and

offers vital

of healthcare

decision support; and clinical
to augment the care

lag,em,ent of the

chronically ill (CCM diagram, Appendix A).
The CCM can be implemented as a whole, or as individual components. Both
approaches aim to improve care by coordinating treatment activities. The complete CCM
has not undergone

"'-V.'UUJ

components have been

controlled ."'''' ....1''.

in well-designed studies.

UL..<U,,'U
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of components of the CCM

been

studies exploring congestive
of 39 studies by

care

the

failure, asthma, and diabetes.

a

and Grurnbach (2002) examining

JJUU\VA.1.W..,HU."'l

authors reported 32 studies showing improved outcomes using at

least one process or outcome measure. In this review, no single component
was found to
components

more

than the

Additionally,

was not a determining factor

number of CCM

improved outcomes.

need to address chronic care management is highlighted by

(2002) as

CCM

.l.JV ..... vLJ,.U ...

UU"',

"tyranny of the urgent."

and
the

anxieties experienced by patients who are more concerned about their acute physical
complaints than
Additional

on-going management of their chronic illness.

are in
care

include

mCenlnV(~S

for

include rushed appointment schedules; minimal to little time to review vital laboratory
inadequate education for patients on the importance of medications, diet,

values;

and follow up care. This phenomenon can

especially true for individuals

who are newly diagnosed hepatitis C who may require more intensive education related
to their disease. One example is

heightened ....

U/U".,L"'"

experienced by individuals as

they attempt to identify the source of their exposure to the

likely occurred

decades
Chronic care

lagemem takes

venues. Individuals

three

care from resources in

community, healthcare

institutions, and by a "",r,un,cv of healthcare providers (Bodenheimer, Wagner et al.,

2002). As the nation's 65-year-and-older population
illness will be at its

resources to

Baby boomers vU"""_HF,'" traditional approaches to care
41

and continue to show more interest
care (Bodenheimer,

and self-management SITl:llrell

Holman, &

CCM, patients are

~UAV"''''U.

in their

2002). By applying

navigating the complexity of overlapping healthcare

through development of collaborative practices.

Chronic Care Model Components
Community Resources and Policy
Advocating for changes in healthcare policies is an important step
how chronic care is delivered in the community.
part of community, institutions,

involves

that

2010). These changes

the

help
efficiently

approaches to care. This may

rethinking on the
and changing

leaders.

outdated healthcare delivery policies and avoiding duplication
of healthcare

redesigning

services are examples

of chronic care management (CCM,
enc~oUlfa~~e

costs

newer, innovative

to improved coordination of care across organizations

patients to 1"I<I."1",(',n<1

chronic care

programming.

Healthcare Care Systems
One ofthe primary goals ofthe CCM is to create cultures,

and

mechanisms that promote safe, high-quality care (CCM, 2010). To accomplish this,
senior leadership within

to

are now

care lanag<;:m,ent facilitating care coordination within

in redesigning chronic
between

coordinating communication, and sharing data across healthcare settings. Continual
nT,v"",,"'"

m

improvement was ,",,,,,un,... an essential

for healthcare systems as

to errors or newly defined healthcare problems arise.
42

,",,,<UClA"'__'

are

Self-management Support
Self-management support is one of the most important elements
Regardless of the setting in which patients receive

CCM.

care or by whom,

patients are

of their chronic illness. Establishing collaborative

held accountable

partnerships with healthcare providers and patients changes the paradigm of "who is
control." Self-management is highlighted
traditional types of care where

a contemporary

are

compared to

control (Bodenheimer et aI., 2002). By

working collaboratively and encouraging self-directed behaviors, patients can make more
informed decisions about their care that will serve as further motivation for continual

Collaborative care is

a driver

encouraging patients to take ,",Ul"'''''"''

of

their illnesses (CCM, 2010). In traditional care delivery systems, physicians are the
instructions on treatments,
compliance (Bodenheimer, Lorig et al., 2002).
mutual respect

evaluate outcomes

collaborative care

on
there is

providers as being the most knowledgeable about diseases but patients

are recognized as the expert on themselves and their lives. Jointly establishing
achievable goals in treatment and evaluating outcomes based on patient's expectations,
confidence, and motivation can ultimately invigorate sustained change. It is important to
note

the CCM that the emphasis shifts towards the patient being
with

education

by healthcare

Lorig et al.).
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primary care
(Bodenheimer,

Delivery System Design and Decision Support
Components

CCM support the integration of evidence-based care in
part of the

"""'T"",.,.. ..... 'v,"',!".", defining team member's roles

and responsibilities improve efficiencies and effectiveness of care delivery (CCM, 20 10).
Additionally, utilizing case Hl".ua~",",u
care supports

gm~r-~aarLoaros

complex

and

evidence-

in care delivery and encourages appropriate follow

up care. Collaboration between specialists and primary care providers offers continuity
and

........vuF.

healthcare systems (CCM).

Clinical Information Systems
The

component of

CCM is clinical information <'''''TA'''''

pertinent data can be

world of
eXl:ratJolatea to ensure comprehensiveness
central component to
means to

CCM (McEvoy &

treatment plans. Patient registries are a
LaA,au,""

2008).

act as a

necessary surveillance testing and follow up schedules. By doing so,

these registries

a proactive approach to chronic care management (Ortiz,

2006). Registries can be established without
most facilities
"F'."'>""''''':>

In the advancing

availability of an electronic health

access to common software tools such as

where

can be formulated (Ortiz). Electronic

and communication patterns between providers

of care
care (CCM, 201 0). Ancillary

and correspondence between providers are examples where coordinated efforts are
encouraged within

component of the CCM.
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CCM and a Community-Based Hepatitis C CUnic

The Chronic

Model provides a conceptual framework to further

complexities of treating individuals with

of the model components

address explicit challenges in providing
U"'.llUJl>L."

the

to this population. The model serves to

between research and practice by

practice and

the

C'll .., .... r..ri

the use

evidence-based

a collaborative approach to care delivery. The CCM was used as a

framework for program development

the community-based hepatitis C treatment

clinic along the shoreline of western Michigan which was conceived as a DNP project.
Although

model as a whole was used to guide this project, focus was placed on the

self-management support and decision support components

developing the HCV

treatment nrl"rrr'<:>rr.""',
improve chronic care management for individuals with hepatitis C
of

community,

to inadequate healthcare
this agency

project included increasing awareness of community

example, one community

resources.

\JH'-,VUL

this

p,.n.,,,,,r'.>

to solve

and lack of social services.

by

patIents to participate in educational programs on u..I':'.""a.:>""

management. Collaborative efforts established with this type of community agency can
the HCV treatment

the

As a healthcare C'uC'r"",..,."" component

the CCM,

were a major focus of this project.
to

found

UUJ."""""''''

HCV treatment program

and cultural

highest rates of hepatitis C continue
the

populations. It is

""0'.",...,

term success

any

providers and staff convey supportive, non-judgmental
45

attitudes on

"how, when,
of hepatitis C

where" people were infected. This
at the same

conveys

partnerships to

improve health outcomes.
Self-management "UIJ'lJV' was the primary component used
treatment regimens

Care

monitoring

nt"'"'''''''''

and require the patient to adhere to

In addition, most patients

require self-management at home.
nutritional intake

project.

medication side

<>TT<>I'TC'

may include treating skin

to nausea, and/or 'V'"""''''''''''" activity

which

adjusting

to reduce

Establishing strong patient-provider relationships encourage a collaborative approach to
self-management as it ."'"••"'''' to hepatitis C treatment. This includes vital education on
expectations

the anticipated treatment regimens;
and required follow up care.
was another "" .. ","nt.

Decision

component of the

when """"","'-'1.'';)1<)'1<5

most .........A'r1""""t "" ... """t" of

this community-based hepatitis C treatment clinic.

was to develop an evidence-based, innovative approach to improve health
outcomes.

guidelines

current literature

delivery established for this community-based
were developed

~.,,~ ......

the approach to care
clinic. Collaborative partnerships

local prc)te!,SHma:1S to gather

healthcare ..... "vll-flU)•...,". To provide for

'-"'-''''H1,'''-

relative to hepatitis C, written materials were

....... "I1P'11

variety of

education of patients and
for accuracy.

'UJAn"'"''

importantly,

to be involved in decision-making whenever possible during
their hepatitis C treatment.
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Lastly, congruence «u"vu.!". the clinical information

in the community-

hepatitis C treatment clinic was challenging. Although the

(EHR), the HCV clinic did not.

had complete access to electronic health

Therefore, all documentation and communication was

11.11 ....." ....

verbally by telephone. The quantity and coordination
and cumbersome.

hospital

was redundancy

with

copies or

paper documents proved to be
paper charting in

to

for a monitoring ""<,t,,,.n As a new clinic in an already

adequately

established ambulatory setting, multiple challenges were encountered including a lack of
community awareness of hepatitis C services; shared physical
and

including phone

machines, poorly coordinated document exc:nrulge and miscommunication;

and an unorganized process for scheduling patients.
Summary
The chronic care model can be used to
illnesses. This model
to
clarity

CmIra,~eS

collaborative efforts

guidance

"''''.VUj,,,,

the CCM provided

program development for this community-based hepatitis C
the shoreline of westem

management support
address known

for

healthcare professionals in

evidence-based care. Using the components

treatment clinic

lJ ... w,,-,.n

the care u.,,'u... !".....

HH'VUj'F;"''''

The

components of self-

decision support especially guided treatment programming to
to hepatitis C treatment Ultimately, the quality of provider-

relationship had a

impact on the

ability to manage

chronic

illness. Using the CCM, the project remained focused on mcreaSml!! access and
health t'\p"(,PlntU\t"i for individuals with hepatitis C.
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CHAPTER 4
METHODS

purpose of this vU'''UL',",' is to describe

methods and

used to

develop and implement a community-based, multidisciplinary hepatitis C clinic in an
underserved area near the
COllceptulau:zea in four

.!],'~~_!],·~:r''';H''''''''

project

west Michigan.

L""",,",,_"CL"'L

phases (a)

of community

development and implementation of a community-based

n""''''T1!T1

(b)

C clinic, (c)

including summary assessment of barriers to treatment, and (d)

program

outcomes as

1"'Ir~\rrr"'rn

occurred

hPT1,X!p~'n

relate to

rnr,rn"J .. n

February 2010 and

access to hepatitis C care. This

2012.

need to improve care for individuals with hepatitis C

west Michigan

community of mtc::re:st was a long-standing goal for heaIthcare providers.
primary care providers sought solutions to the lack

adequate care

hepatitis C by first approaching senior administrators from
to find solutions occurred in
physician who was treating
sources

care for

n"'rcnn

spring of2010

numbers of
with hepatitis
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patients with
hospital .""",t"rn

the sudden death
served as one

a local

the few

Establishing Hepatitis C Initiative
The Community HCV Initiative was a grass roots effort by interested
professionals and the concept was presented to hospital administrative leaders in July
2010. With resounding support, a taskforce steering committee was comprised of a
doctor of nursing practice (DNP) student; a local physician specializing in infectious
diseases; the executive director of a community agency focused on services for the
underserved; and the Vice PresidentiChiefMedical Officer of the hospital. To
adequately access the problem and determine the best evidence-based approach to
program development, ample time was taken to review the current state of knowledge
related to hepatitis C. The DNP student assumed responsibility to review literature on
HCV treatment models and summarize existing guidelines on treatment management.
The review of literature on hepatitis C was limited relative to optimal models of
care delivery for persons with hepatitis C. The review reflected a growing interest in
HCV care and reflected the limited number of published studies on HCV models of care
in the US. The review also included several studies from Australia and Canada
describing particular challenges that were encountered as HCV -dedicated clinics were
established in their local communities. Consistently, these findings suggested that a
collaborative approach using expertise from multiple disciplines would be useful in HCV
populations.
Congruent with the established timeline, members of the Community HCV
Initiative steering committee met in January 2011 and reviewed the initial literature on
models of care for individuals undergoing HCV therapy. A mUltidisciplinary approach
was selected because ofthe dominance and success with this type of programming in the
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literature. A multidisciplinary approach to HCV treatment was
clinical approach to address
U";;va,J,;:>v

models in

of the hospital requested a draft job description

ne(~aea

as the

by those ala:gnosea with HCV (Appendix C).

of the success with other

included a ~'V,'U"''''U'U

£1PI'PTlCr1

countries, administrative

.~~.~~"v

a nurse practitioner (NP). The request

ne4:::esSary education, 'V-",,""'LL'"

and a list of

skills

to manage HCV treatment in collaboration with an infectious disease physician.

During this meeting, a list of potential community stakeholders was developed with the
to

the HCV

to

opportunities for partnerships. For the purpose of the

'.U"\.'HUl.la

nr"'\lp'~T

and explore

community stakeholders

were defined as "n~'r<!r,n who have direct or indirect influence on the quality of care for

"

individuals with hepatitis

Meanwhile, to better understand the needs of local primary care providers, a
Assessment was developed. This survey was designed

Community HCV

HCV

to examllle

_~..".. ,..,

behaviors of

and to explore barriers, including access issues to HCV treatment. The
with an introductory cover letter (Appendix D) explaining
physicians, nurse practitioners,

physician

was sent

project to nearly 200

Unfortunately,

email

pediatric OTIICeS who were unlikely to

included
treatment.

Community

C Needs

was
th

deployed electronically through Survey Monkey on March 18 2011. Of the nearly 200
providers surveyed,

(11

responses were collected. Although the survey response

numbers were limited, the additional comments submitted by PCPs were helpful in
delineating

need

comprehensive community pn>gr;ammlng.
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next
who

was to meet with nn.1t", ... t.

III

community stakeholders

be willing to act as "partners

took place on April

A taskforce meeting

2011 and included members

HCV Steering Committee;

the local community public health department; pharmaceutical
community "r.'~U,""V'"

healthcare .... ~".,,~Jlu.'"'..., to address

treatment. Physicians and leaders
(FQHC) also attended in an

",rr'>t'YI1n.i"

interested
psychosocial

hr.>?.... "" .. "

to

local Federally Qualified Health

to network with key players involved in the

Initiative.
During this taskforce meeting, a short presentation on the dilemma of HCV,
barriers to treatment, and a review of
Additionally, the

literature on various

treatment models was

of the Community Needs

were reviewed

and discussions ensued regarding the implementation of a community-based clinic using
a multidisciplinary model.
a result

the taskforce meeting, committees were

various sUbspecialty

April 2011

",£1ri .."",,,,

oet:mt::o essential for a dedicated HCV treatment clinic.
committees met with the DNP student and, when indicated, the

of the
collaborating

to

un,","'''J'''''>

April

disease

Dn'VSl~'::IaJn.

The

VV',UH . .

met at various times between

2012.

Multidisciplinary Partnerships
order to establish multidisciplinary partnerships among

six subcommittees,

the DNP student met with various members on 12 occasions to discuss collaborative
"'++"....+"

in improving care

individuals with hepatitis C
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those _•. ~.~.,.,~

treatment.

Appendix G is a

listing of all potential mUltidisciplinary partnerships for

HCV clinic.

Psychological and addiction services.

January

presented to a group

50 community mental

challenges of ""''''4'''''",-

C in individuals

the presentation was to

the eligibility

12, the DNP student
case workers to describe the
One main
hepatitis C treatment

the need for evaluation on a case-by-case basis. Some case workers among this group of
professionals voiced concerns as they acknowledged

rates of ineligibility among

their patients with ''',",uu"", illness. The case workers were educated on the need for an
extensive follow Up .".au,.""

common medication

""'/"'/",><,1",,

eligible for treatment.

initial HCV clinic
_"'J>~""'_~'

evaluation,
multidisciplinary

clear and consistent

referral, and

were shared and

Community "' ...."... ".• ""'" Members from community
discuss resources

for those deemed

U",""H'"

information
Options and resources

agencies met to

for the underinsured and

individuals. This included

prescription

services.

case management and

in locating primary care

providers were also
To address the
public health
importance of

for reportable diseases, a nurse from the community
met with the DNP student to

of appropriate

communicable diseases

educational

route of HCV

established databases.

the public health rt"... ",1"1"'n'>
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policies regarding the

,.<>"",(\1"1",

laboratories to
attempt to cross-

reiiereJtlce:d all

V"".lvU''''

from historical databases

Disease

pennanent

into the Michigan

(MDSS).

Pharmaceutical

On multiple

phannaceutical

met with the DNP student and physician to

ref)re:serlta1:iv(~s

issues related to HCV education and

treatment. Phannaceutical representatives provided infonnation on patient assistance
nrr,crr<.rn"

as well as provider and oalCleIU educational infonnation.

HCV treatment are extraordinarily expensive and often
It was concluded that

benefits

medications for

pnor

......... ,,'v ..

filling of prescriptions might occur in a variety of ways.

specialty

include

refills;

the PA oro,~ess providing additional patient educational materials; and
assistance
ambulatory care
conflict

(PA).

laboratory monitoring.

In

some cases

HCV clinic is housed in

the use

from

the local hospital phannacy.

"LI'-' ....

1<,"' ..

team

and

communication a priority. Additionally, a hospital phannacist was approved for
part-time employment in
had not

hepatitis C

of this appointment

although

been confinned at the time

project conclusion.

Michigan Hepatitis C Advisory Taskforce. The DNP student met with the
Adult Viral Hepatitis Coordinator from
(MDCH) to discuss policy issues in

Michigan Department of
state of

related hepatitis C. The

coordinator ".. <un.,,", the Michigan Hepatitis C Advisory Taskforce
This governor-appointed

Force

,",V.<U . . ,,,,",

Health

2007 to

10.

21 recommendations J.V\',U':>.UIF; on the

following priorities: Increasing hepatitis C surveillance efforts/improving the quality of
hepatitis C surveillance data; developing

needle v"''"'U''''''F,''
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,",U'-'UAF,

syringe access; and providing other hepatitis

use

to people who

drugs; and facilitating access to hepatitis C screening, testing, management
treatment (MDCH, 2010).

Educational offerings.
the

further develop their

providers at

clinic attended several seminar and educational opportunities. These

increased

knowledge

confidence of the providers in treating hepatitis C patients

with Direct Acting Antiviral (DAA) in combination with interferon

ribavirin.

Planned educational events by physicians from tertiary, research institutions offered
expert
u,.,,,u~•...,

on HCV treatment regimens and challenges. In addition, an infectious
colleague

another community met with

student

the

collaborating physician to review treatment guidelines, discuss community reterr,al
options

reimbursement, and
the

to

~ol:")~~'

strategies for monitoring. This opportunity

insights

the standpoint of a

C treatment

community-based clinic.
in another community-based HCV

DNP student spent immersion
treatment clinic managed by a nurse practitioner
experience allowed the

infectious

student to gain ...~.,..,...~ into

YAY',",U.,,,

IJ"'Ll,""UL

physician. The

processing, treatment

protocols, monitoring strategies, and develop networking relationships with
collaborative team treating hepatitis C.

Collaborative Efforts with Federally Qualified Healthcare Clinics
To ,Tn . . . ,,""'' the care
local

individuals with hepatitis C in the

the DNP student,

members

infectious disease physician met to discuss

collaborative efforts to optimize access, oU1:COlme:s, and reimbursement
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servIces.

majority of individuals with

C

psychosocial

challenges as well as health and financial concerns, it was ",,,:.u..u,,,,,,,

a

portion of

patients with hepatitis C may be established patients
collaboration between the FQHC healthcare ............,H."
was seen as important

care.

a way to measure

Hepatitis C Treatment ......,~ ....."' .....
The

of program

1. The

completed over 400 hours of clinical

to

community partnerships, plan and coordinate clinic prc)gnmllmn

obtain

DNP

approval for program evaluation.

Program Evaluation
Setting and Participants
The hepatitis C treatment clinic was established in a ,.,A ..... """""
along the shoreline of western Michigan.
a mUlltl(llS(~lPJ

setting. Clinic programming sought to overcome perceptions
population included all adults with HCY

uu~~ •• ~ . .

over 18

to care. The
who met

~L""'''~~ " ...........,...,,........

to allow select data extraction from
consent documents were maintained as part of the . . . "t • .,.",!'
inclusion

included those individuals referred to the hepatitis C clinic for

evaluation of treatment. Exclusion criteria included those who did not
consent

located

was seen as essential

to evaluate the effectiveness of HCY treatment

agreed to participate, and

"~.'OJ~~~'

patients under the age of 18.
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Instruments
JLJL ...' .........

"vllUU'-,U

perception survey. A

to

(Appendix I) was

data regarding oel'celDtU)llS

resources believed to

hepatitis C treatment. Select
and variability relative to

data was collected to detennine
.~ . .,u . . ._u

no".",.,T

treatment programming. Demographics included

to assist in further

gender, hepatitis C genotype,

C treatment history, and the county in which the patient resided.
PVT'1'l'l,...TPI1

on

and frequency

mtt::rested stakeholders.

collection steps. The survey was

to patients at five specific

however, timeframes between

np,'U'F,.,n

varied among patients due to their
testing/consultations

in starting treatment and any
the various surveys.

the patient received the Patient

first survey collection
U,uI\,.UJUL

(Appendix J)

to complete

~ . . . ., . . .u

completed the surveys by

along a 200rnm line

indicating their perception of the illness
discomfort
was

short 6-question

completed in less than 5

The
minutes.

was

reterr'als to provide

programming

personal 'I"'I1',·t"""",,

llUIJU\,.

questions. A potential

a patient may have included an

A . . . . . ..., . . , ' ]

or an inability to read. In these cases,
were

the 1.1""',""" with the survey. Completed
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to comprehend what the question
nurse was available to
added to the .......

. " v. . .

se(:onld survey was

to

of the survey
.u...... ..., ... "....

physician consultation

I"'\I'"f'ol'P'"''

Again, the

with an "x" to reflect their perception of the illness-management

third survey was distributed at

time of the injection

management session and
The fourth and

manner above.

in

were distributed at the

seCIDnd follow up (2 and 4 weeks

treatment) and completed in

a manner congruent with other surveys.

Informed consent collection. Informed consents were collected by the nurse(s)
who

C treatment clinic.

in

.,.".......,,<."" of the project and to answer

to
of data

nTr\'I""YY.ArI

treatment at
who were no
discuss the
revIew

consent was requested

V""''''UL.;)

who were receiving
For those individuals
to contact

obtaining services at the clinic, nurses
request consent. Patients were

1"'\1'"(\1PI'T

consent if they agreed to allow access

board. A request

Mercy Health Partners, Muskegon,

This project involved

selected information from

obtain program evaluation data for the community
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to

to come in person to
medical record.
<>T""tTr.""'T

1-4) review was

at

by the Institutional Review

submitted

to

questions.

a scripted approach

Institutional

State

were trained by the DNP student

-"'l"~"

Valley

(Appendix Land M).
patient surveys to

C treatment clinic.

Data collection and evaluation tool. Data collection was accomplished by using
a retrospective chart audit of existing medical records to examine selected demographic
information and data regarding
treatment.

of available resources believed to

was obtained from patients seen at the

1,2011 and March 15,2012. A Hepatitis C Treatment

vrnn,.<l1'Y\

(Appendix N) was created and

between October

Evaluation Tool

health oer'cel:'ltlC)ll

To de-identifY patient information, a corresponding sequential alphabet
character was

to each participant. The DNP student only accessed

who agreed

charts of
,",'-'V'l"'.;)

~u,."" •• _~

once unless

marked only on

written consent and only

<UH,HUJLVH

A master

medical

character code was

of participants was

ona

a secure site.

health perception questions were reCO[(lea by measuring

The results

patient has marked an "x" along a 200mm line. Quantitative

point where
u,uu." ....

was required. The

program evaluation

password orc>tec:ted computer

.... 'V .....

of the

a.I.J",I.J";~I.JU

medical

by measuring

length from zero;

a2mm

were

equated to 1%

their responses.
Program Documentation
programming development, electronic medical records were

At the time of

clinic areas within the hospitaL

not accessible

assessments and monitoring

organization of the ...... ', .... "... chart" as
developed
U''-''LU",,,,

community

a Problem

with

forms.

UllJLI.JHLULJlVU

dm~cte:d

required creation
forms

by the physician.

C clinic can be
effect mama:gernellt strategies;
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COITe~;oondt~d

paper
to the

documentation
in Appendix 0 and

Notes;

Medication Reconciliation; Pretreatment

Laboratory Monitoring

Flowsheet which

and treatment medication

documented vital signs for

dosages; Intake

History; and Laboratory

In addition to
developed to

forms for the medical record, .au.....""' .... ",,'"'u letters were

communication between

(Appendix 0).

ophthalmologist/optometrists

...'"' ....,."''' correspondence to

individuals requiring pretreatment eye exams and a

to primary care providers

informing them that their patient was seen at the
referral. A specific

but required additional

was developed to the primary care providers addressing mental

illness concerns

active alcohol use.
an additional informed consent

completed.

or

mt4)mled consent addressed

Llve,,",u...

C treatment was

treatment side effects;

medication and follow up compliance; and contraception information. Patients were
asked to sign the consent before starting treatment

Clinic Service Coordination
Treatment
hepatitis C treatment

One of the most important steps in
to have a

"' .......... 'lB5

published guidelines

2009,2012).
for treatment

treatment. The most recent

of national

as an addendum to
LUY.,."U'. . " ' "

was

published previously (Ghany et

encourage patients to

this way former myths

avoided.
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i:1:::':::"C;:::'~'C;U

on a one-to-one basis

eligibility requirements were

Clinic Protocols
to the algorithm of how

Clinical protocols refer
how

access

the

C clinic.

lJ'U'''l1C;)

were rp1",~rr"11 and

with any new program, there

was flexibility in these protocols until more knowledge was gained through experience.
Referrals. Patients were referred to the clinic in a variety of ways. The .....~.T""·..,
or phoned 1'''t"'~rr''' from

method was a

allowed patient information to accompany

,... ..11m""",,

care provider. Faxed referrals

requests; phoned referrals required the

of

added

received between

October 1, 2011 and

word-of-mouth ....u."' ....'u..",,,

that the clinic was available for referrals.
HCVeducation. Adequate and accurate education was seen as imperative for
patients

hepatitis C who were COilSHlefJtng treatment (Birkel, Caldwell, Stafford-Fox,

Casarico, & Benson, 2004).
program '"'''''_'''C........ models
determining how

design and development of the hepatitis C treatment
design

literature and

would be educated and processed

clinic played a key role in
the clinic

et

aI., 2011). As established, the program enhanced education of the patient on
ofHCV; described treatment and possible side effects;

reviewed

term

and

patients on the em~ClS of alcohol and HCV. During the

clinic

treatment eligibility and medical

evaluations were made
compliance concerns were aa(1reSSt~a In

maybe

scheduled in a group setting. Most importantly,
""""""P'C'''' of developing elatlOlnSllllDS between

team.
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initial clinic appointment started
patients,

and hepatitis care

Physician consults. Patients were scheduled for a physician consultation
they

aTIe:nm~Q

the

At

of the

and physical were completed; additional
patients were given

up studies were identified; and

time for their ""...,.,uv,.", to be answered. Requirements to

determine eligibility for treatment involved
including compliance "".".'-'''', results
exam,

education was reinforced; a

consideration

multiple 1aC:I01'S

liver biopsy, imaging studies, blood work, eye
other medical specialty such as

to psychologist or psychiatrist, or

cardiology, endocrinology, and gastroenterology.

Pretreatment testing.
completed to

rlplrPM"I"I

I-<PTnrp

therapy could begin, all pretreatment testing was

underlying liver .....

J".., " •• 'V

or

co-morbidities that

information, along with an accurate psychosocial evaluation

treatment.

ultimately determined treatment eligibility. Required pretreatment

is shown in

Appendix O.

Announcement Letter to Community Providers
hepatitis clinic to the community was

A formal announcement introducing
on February

2012 (Appendix

communicated that the clinic

In this introductory

it was clearly

was first attempting to "'....'" ..,,:1 patient volume within

the community and encouraged primary care providers to assist in

referral process by

having their IJ""'"U.''' complete the required preliminary work

Hepatitis C

Clinic Staffing

Estimating staffing

for the
.... T"'rt .. ' .. T

hepatitis

servlCes. One

was difficult. Throughout the
(September 20 II-April 2012) coordinated all

registered nurse was minimally involved
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collecting

clinic rpt,>rr<l
consents. On a

nn'"<lH''-''

monitoring.

collecting infonned

.... ""'1V""', a medical

patients

was """''''''0'''''''' to the HCV and roomed

signs and weights, prepared charts, and assisted in making

copies of chart documents.
a meeting was held with
manager, and
After

L",",,"'LV . .'

officer to

u,. .,,., ... ,,,,,

UU"V"'UU"P;

"",",U,.H

for the

uu"'.""''''''''

O

......,.vv. of incoming rpt,>rr<l

monitoring and mama:gernellt of hepatitis C treatment,

physician, the

.p;u,..,.. ..,'"

required for

group agreed to move forward

with developing a position for a nurse practitioner to work in collaboration with the
infectious \,11"''''a;:'.... nn'''o'i''

At the time of project

a business plan was

being fonnulated that would require eventual approval by
To secure ,,,,,,u,,,,,,,,,•..,

hospital finance committee.

operations, a fp.,,,tv,r<,,,-., n,"'Cn'IIU'I was posted

hospital for a part-time nurse practitioner at the conclusion

the

project.

Outcomes Evaluation
To evaluate improved access for hepatitis C treatnlenl, healthcare providers in the
community were <',n''''''''<>£1 at the completion of the project. ",.... ,"".,'" were completed by
providers who
Q) mirrored

infonnation was

survey (Appendix

a Grand Rounds event on
for the Community

rl."'''....

HCV screening nr<ll"1"ll'p

'''''1U.... UL

in that
barriers to

HCV care, Infonnation reviewed at this seminar included magnitude of the HCV
dilemma, known

to treatment, and expected benefits of

hepatitis C clinic.
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community-based

f"Irr"Pt'T

care

was developed with

COlffiJ:lonlents in order to improve

individuals with hepatitis C

of western Michigan.

assessment was

the necessary data required to

to

convene and convince institutional leaders to champion this cause. The project was
and implemented with knowledge
F.,.." ............ ,,'"'

F. .... ,,, ........

from components of the Chronic
assessing the health

treatment.

from the literature review and
Early program evaluation was

f"Ip·..,..P· ....t'I\t'I

an outcome assessment was

......,... .,./""',,'1"'" on their perceptions of the

1-"... ,."'......

. .", ...,<vu.

relative to common v ......'"' .• to
oJ

and analyzed from

care

meeting their patients' needs .
dozens of community

place over a two- year

hepatitis C treatment clinic is now

The community-based,
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5

The purpose of this project was to

access to

e nealmem and
e

report patient's perceptions of common
treatment. The project was
(b) development and implementation

a COllliTmnny-oasea

program evaluation as it relates to patient's

e clinic, (c)
to treatment,

""1",""", ...,1"1

and (d) evaluation of program outcomes as

e

""""''''''1"1 access to hepatitis

care. The results reported reflect the
hepatitis initiative outcome survey, and the health perception survey. Data
the surveys was accomplished by

the Statistical

(SPSS) software.

Community Needs Assessment
Approximately 200 emailsweresenttothe .......

a u ........

a
the

network with an introductory note and link to an
purpose of this evaluation health care providers
and physician assistants. Results of the survey are shown
who responded to question one, the
with HeV in their practice in the

calendar
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1%

had seen

0

patients; and 17.4% had assessed 11

hepatitis C patients. Questions
were very likely or likely (30.4%

routine screening procedures. Most
34.8%, respectively) to routinely

their IV drug

of providers (69.6%) would

nelJalltlS profile if the patient disclosed

drugs. These findings

are aware of health

IV drug use, yet they

about asking about
of blood transfusion, only 39.1 % of the

However, when inquiring about
were somewhat likely to ask

I-'''"L .....' ' • .,

an area where further education is

about a previous transfusion, suggesting

ne~~aea.

Survey questions pertaining to
.. ",,.,,,yt,,,,.rl

rpt~'rr~

of patients with hepatitis C (Table 1)

that 67% of the reSPOlloe:ms were
C treatment,

or likely to refer

1

providers (47.8%)

to

I"UL1........,

patients for treatment.

were very likely to encounter barriers in

patients referred for treatment.

respondents, 73.9% indicated they would

very likely to refer patients to a

C treatment clinic, while 8.6%

they would only be somewhat likely or unlikely to

to the hepatitis C clinic.
assessment, healthcare

At the conclusion of the community

the opportunity to submit additional comments regarding specific
",VI,""",

were
to

15 providers responded and

their patients treated for hepatitis

insurance, and

lack of access to
psychological/social

is

as

to treatment.
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1

Community

Assessment

Item

n

Very Likely
n (%)

Likely
n (%)

Somewhat
Likely

Unlikely
n (%)

23

7 (30.4)

8(34.8)

5 (21.7)

3 (13.0)

3. How
are you to
order a hepatitis
should the
patient disclose
their use of IV

23

16 (69.6)

2 (8.7)

2 (8.7)

4. How
are you to
ask a routine
about their
blood transfusions?

23

7 (30.4)

3 (l3.0)

9

5. How
order a

22

5 (22.7)

5 (22.7)

4 (18.2)

8. (36.4)

6. How likely are you to
refer a
for
hepatitis C treatment?

22

II (50.0)

6 (27.3)

1 (4.5)

4 (18.2)

7. How likely are you to
encounter barriers in
your
referred for
C
treatment?

23

II (47.8)

3 (13)

4 (17.4)

5

23

17

Questions Pertaining
t6HCV
Practices
2. How likely are you to
ask a routine
about a
use?

I)

3

4

should the
patient disclose a
history of blood
transfusion?
Questions
to Referrals

4 (17.4)

clinic?

66

1(43)

Hepatitis C Initiative Outcome Evaluation
Rounds
where

topic focused on

Series was attc:mcled
treatment of hepatitis

completed the Hepatitis C
and

Of those who

Outcome

Several minor '-''''''-''5'_'' were made

to

in attempt to

who

34

20 were primary care providers

were providers from

seen by

49 providers on April 23, 2012

the volume

providers, obtain information on

procedures,

being
to identify those

adopt the suggested age-based screening 5UJ'Y"UH"v. A small
to

the

to better

one man

to find adequate

care as

be referred to

hepatitis C clinic.

those who

had seen

submitted a survey, 23(67.6%)
stated they had seen
within
patients;

how many were seen

provider

to offer insight into

well as how many individuals

had seen 1

patients;

patients

2.

education might
recommendation put

were asked

responses when

a risk-based HCV assessment (question

Once again, this indicates an area

inform primary care providers on the current HCV
the U.S.

~r""""nt",h

Services

majority of providers (79.4%) would order a hepatitis profile if a

disclosed risk(s) of acquiring a

somewhat

last year;

two (5.9) providers had seen over 30 individuals with

was a wide

(2004).

0-5 patients

year; in that same time period, one provider (2.9%) had seen 21-30 HCV

are reported

scn~enmg

was

or unlikely to

virus. Over 20% still reported they would be
a hepatitis profile
67

patient disclosed

Of the

providers who completed
adopt

survey, 67.6% reported they would

likely or likely

age-based HCV screening recommendations.

will should

of patients aware of the

to

ultimately higher numbers of people

referred to the

Of the providers who attended the Grand Round

clinic.
would refer

individuals for HCV treatment. Only 17.7% reported they would be somewhat
unlikely to refer patients

HCV treatment. This indicates that at least some of the

providers from other heaIthcare

<;'Pt"1l1f'I'<;'

would

patients

HCV treatment.

Encountering barriers in getting patients referred for hepatitis C treatment
was reported in 55.9% of responders,
encounter

OJ"......"'.

6)

.2% were somewhat likely or unlikely to

and one respondent, a urologist, did not answer the question.

slightly

Community Needs As:ses:smt~n where over 60%

reported encountering ~ ...... u~'''; in getting their patients referred
treatment. Most importantly, 91.2% of providers surveyed
hepatitis C clinic would facilitate the care for
who reported

or

HCV

the community-based

HCV patients. Ofthe two responders

HCV clinic would not facilitate care for their patients, one AU""U",.,,,,,,,,

himself as a surgeon, the other was not a primary care provider.
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2
Outcomes
n

Likely
n (%)

Somewhat

n (%)

Unlikely
n (%)

34

8 (23.5)

9 (26.5)

10 (29.4)

7 (20.6)

34

22 (64.7)

5 (14.7)

3 (8.8)

4 (11.8)

34

13 (38.2)

10 (29.4)

6 (17.6)

5 (147)

5. How likely are you
to refer a patient for
C treatment?

34

19 (55.9)

9 (26.5)

4 (11.8)

2 (5.9)

6. How
were you
to encounter barriers
your
referred for

33

8 (23.5)

II (32.4)

5 (14.7)

9 (265)

33

22 (647)

9 (26.5)

0(0.0%)

2 (5.9)

Questions Pertaining

toHCV
Practices
2. How likely are you to
a hepatitis C
Risk-Based
Assessment?
3. How
are you to
order a hepatitis
should !.he
patient disclose their
risk(s) for
C?

Questions
to Referrals

hepatitis treatment
clinic facilitate your
ability to care for your
patients?
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Data was further analyzed to better understand
and referral issues for

local primary care providers who completed the Outcome

Survey. The majority

care providers (70%)

in the previous

Of the primary care

hepatitis C

p~"~u....,

was a

performing a risk-based

assessment (question 2).

who responded, seven (35%) reported they would

likely to perform

screening; six (30%) would

somewhat likely; and one (5%) would be unlikely.

acquiring a

seen

seen more than 6 ~'''''''H''''

of responses when

or likely "'.."'A"'''-'

specific screening practices

likely; six (30%) would

helJatms profile would be very

90% of the primary care

screening recommendations

patient disclosed
would adopt the aQc::-DaSf~Q

the

h .. ,,,,,l',,h

HCV screening (question

Of the primary care

HCV treatment, 75%

providers, 85%

very

surveyed encountered

barriers to getting patIents referred. Lastly, 100% of the primary care providers reported
community-based "",.."",.",., C treatment clinic would

the care for

patients.

Health Perception
A total of 47 ..<>,.'3....."

clinic between October 1,

11

201

processed or scheduled

were recent and were not
completion.

March 1

one appointment. Many

processed and seen for at

.....r''''''''T

hepatitis C treatment

were received at

17

reI,err::lls, 12 patients were

early program evaluation. Of the five who did not
county, two had moderately severe mental illness, and one was
70

17 patient referrals were
" , ...........1'>

30 referrals

pOllnnnents at the time of
to participate in
two lived out of the
ineligible for

treatment

active alcohol

v,",,,,u, ... ,,,,,

two patients living out
.... "' ......"','" and the other

to participate U"'''',Q.U'''''
OJ", ...,«u"",

they were deemed

for treatment for various medical

reasons.

one of the 12 patients who

declined

to the clinic one week

L>..I'.• V'.'~

in the early evaluation initially

participants, seven (58.3%) were

to sign the consent.
.""uall'"

while five (41.7%) were HA",.''''''',
Genotype 1 was ....,..,,,,,...t,,,,ri

50 to 69 years old (M=57.75;
one patient was rPr,n..,tpl"1 as
program evaluation, ten

were naYve to HCV treatment (never
and one (8.3%) was a

Nine (75%) patients lived in
to the south, and one (8.3%)

HH'''''HU'~

of interest, two (16.7%)
a rural county to the north.

two required indirect .."'1",'....'"

the 12

In

genotype 3.

having had treatment previously), one (8.3%) was a

lived in a

were

evaluation prior to
one to gastroenterology.

treatment; one patient was sent to
perceptions

hepatitis C treatment are

order in Table 3. In

patients' perceptions of
on a scale ofO-200mm

barriers to care, patients were asked to rank

very little, somewhat, and very much to guide their answers.

using the

two mlL1mneters equated to 1%. Using the scale,
..u. .........

of their
was
somewhat sure

"'.u

IJU"",,'.;) who participated in the

had perceptions of having little overall control over the management
not

C at baseline. Of those,

other 25% felt only

in managing their
what was expected of them.
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90%

patients reported having

inadequate resources to manage their hepatitis C. Only one patient felt they had adequate
resources to manage their hepatitis C. Lack of adequate psychological/emotion support
was perceived by 58.3% of patients, 33.2% perceived they had at least some support, and
one patient felt adequately supported. When asked about support with decision making
(question 4), less than half (41.7%) felt supported in making decisions about their
hepatitis C care, 33.2% felt somewhat supported in making decisions about the HCV
care, and 24.9% felt supported in making decisions about their HCV care. Lastly, over
70% of patients at baseline perceived confidence in their ability to follow a prescribed
hepatitis C treatment plan.
Table 3
Rank Ordering of Perceived Health Perceptions at Baseline
Mean

Standard Deviation

I. Felt in control over the
management of your
hepatitis C

3.05

5.8

5. Understood what was
expected of you in
managing your hepatitis C

13.6

21.3

2. Had adequate resources to
manage your hepatitis C

23.5

31.3

3. Had adequate
psychological or
emotional support

24.9

31.9

4. Felt supported in making
decisions regarding your
hepatitis C

43.1

38.4

6. Had confidence in
yourself to follow a
hepatitis C treatment
regimen.

74.7

37.2

Survey Question
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The limited number of patients in this
sophisticated statistical

evaluation

However, a number

prohibited a more
were

from these

preliminary results. Of the 12 patIents who completed the first health perception
nine patients progressed to a physician consultation and were
two.

4 summarizes

change in mean scores and standard deviations of time one
Overall, ""':>'Ct"':>"""/1 barriers to hepatitis C

compared to time two
treatment

patients

two. Patients' perceptions

of having confidence in following a treatment plan
Improvements in mean scores occurred

of the management oftheir hepatitis C
to

to complete

1 ...... ' ' ' ' ' ......

at high

in both

patients in perceptions of control
an mcreased mean of

How well they understood what was

ofthem in managing their

hepatitis C (question five), had an increased mean of 13.6 to a mean of 49.6. Patient's
perceptions of having

over the management of their hepatitis

both survey one and two.
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the lowest

4

1. Felt in control over
the management of
your hepatitis C

3.05

5.8

22.7

27.9

2. Had
resources to manage
your hepatitis C

23.5

31.3

41.3

36.3

5. Understood what was
of you in
your
hepatitis C

13.6

21.3

49.6

40.1

4. Felt supported in
decisions
your
hepatitis C

43.1

38.4

57.7

38.3

3. Had adequate
psychological or
emotional support

24.9

31.9

59.0

44.6

6. Had confidence in
follow a
hepatitis C treatment

74.7

37.2

77.6

29.0

Summary
results of the
infonnation on the
services for individuals

provided preliminary

physicians' perceptions

the

for improved healthcare

area of interest. Of those

hepatitis C in

1% would refer patients to the community hepatitis C clinic.

responded,

Hepatitis C Initiative

Outcome Survey showed that over 90% of providers surveyed felt the community
hepatitis C clinic would
hepatitis

Additionally, the

ability to better care for

patients with

Perception Survey showed improved scores of

74

health ",,,,,r"""r,J-,

the

one surveys as compared to

two surveys.

75

from time

6
DISCUSSION

This

will further

the findings of this project

highlight

successes and challenges during development and implementation.

purpose

U1",","".,.;)

project was to provide improved access and care
underserved area. The

implementation of a community-based hepatitis C
provider perceptions

clinic; enactment of an evaluation plan;
",H'.,..t",

put
individuals

early ......r.·l"M"<>

developing and implementing this
hepatitis C

The project required enormous support

n,.r"",,'T

this community of

improved health perceptions of patients rp(y",.,n.n

committee

hepatitis C in an

was developed in phases including evaluation

community need; development

outcomes. The

individuals

and

to treatment.
the Hepatitis C Initiative steering

institutional leadership. Their support successfully motivated other
providers to complete the Community HCV Needs Assessment and the

Hepatitis C Initiative Outcome Survey. The
validation

local

hepatitis C
to

supported

of the

that improved care was

provided the necessary
nel~aea

establishment of a
hepatitis C patients.

the provider's ability to care for
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for individuals

hepatitis C

The use ofthe chronic care model for this project provided a critical
for the exploration of

and facilitators of hepatitis C care defined
,.,,1'1,,'''' ,.,,,,,.pnr provided a focus for program

The CCM guided
served as the

1-..

ne,~essaI"Y

evaluation. While all of the components

were utilized for

cornp(mems of self-management support

delivery support were

VUJLUUL/5"

that Df()m·ote:d successful outcomes.

provided

the healthcare system,

hepatitis C clinic that

interactions between a

team

an

informed patient.

Provider Surveys
A relatively small number of responses were received from the Community
Assessment and the limited .......... v'v. was attributed to the fact that surveys were
to all providers in

health

of their potential to

n..,.Tuln1r ....

hepatitis C community

hepatitis C treatment. In retrosoe<:t.
assessment to

""u","",",y

helped to ensure a

most

response. This may

augmented by mailing reminder nn.,"tf',,,,.rI to

who had not yet responded or ",,,,.,,,,,n,,/,; a follow up email. In addition, the
response time between the
responses rates. Yet, the

launch and deadline for replies may
Needs Assessment validated concerns

C

services for their patients with

from providers regarding the
C. The additional comments by

providers at the end of the survey were u,,,./5,, ....

helped to catapult the
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and

surveys attempted to identifY the

patients who were seen by

providers in the community. The response

between the surveys; the

of providers responded having seen

C patients in their practice

year. In retrospect, a zero value should
the opportunity to

added to the survey
had not seen a hepatitis C patient

the last year. The survey
l.n.... ".A"'-'

lack a true understanding of

are seen by

of interest.

_,..., ___ ~ to screening procedures
pra,cnces among providers. To date,
"''''A'~'''AAUAF>

surveys showed varying

l':>J:'I.'-UQ.,.;:o\#U

assessment remains the guideline for
2004). It is widely rpn,.....rt~'r1

for HCV (US Preventative

that only 25% of those infected with HCV are aware of their diagnosis. The current riskassessment is inadequately identifying

individuals. Age-based screening
screening and is reported to

presented as a viable alternative to
numbers of people aware

diagnosis. The Grand Round

to pre:sellt

age-based HCV

majority of providers Qllr"p~,'Pri

In'"'I'-''' ....,''''

"'"."'. . .,'u,,'''"' recommendations. If

would likely adopt the
community providers,

of individuals referred to
Generally, the surveys effectively

'-''''~''''''''''

C clinic can be expected.
a,;,Tt'lp,rpri

survey for the Community

needed information.

more 1'",,..,,,,&>1'<,1'1

would have yielded more optimal

In regards to HCV screening, the

validated inconsistencies in using

assessments. To improve the care

with hepatitis C,

to be adopted.
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Project Development and Implementation
From the initiation of the hepatitis C project, evidence-based practice guided
program development. However, defining program protocols and establishing adequate
paper documentation consumed significant time in the early stages of program
development. While initially this was a time concern, this early detail proved to be
exceedingly valuable. Establishing the medical record for completeness and
organizational flow was necessary prior to patients being scheduled at the clinic.
Additionally, unanticipated challenges presented included designing coordinated clinic
schedules; establishing efficient processing for patients during the work up phase of
treatment; and reducing fragmentation of services.
The unanticipated chaUenges ultimately affected the number of patients who were
seen at the clinic during the project time period. Time constraints and the community
announcement letter about the hepatitis clinic lead to several patient referrals not being
processed by the project completion. Those individuals who were not seen for an
appointment received a letter and were informed they would be contacted when
permanent HCV clinic staff was secured.

Program Evaluation
Early program evaluation provided preliminary insights on patients' perceptions
in navigating barriers to treatment. Although the sample size was limited, early data
trends showed improvement of all health perception questions between survey one and
survey two. Patients generally felt confident to follow a treatment regimen which may
prove to be beneficial as they move through the stages of pretreatment work up and
treatment initiation. Of the surveys collected from time one to time two, one previously
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on

all health perception questions. Because

was

the perception scores related to patients naIve to

treatment.

Limitations and Challenges
this project. Some of the '-'U'U"'U5'~~

Many
Dle:m~~ntmg

____ ,.., __ area

this project may be unique to the

For example, the location of this project was in a
where most providers know each other. This
more steadily than in larger communities. The DNP

project to move
also known

was

community and may have allowed collaborations that may not

In

other communities.
project focus on the challenges in developing a new
without a dedicated

and sufficient technological support. In collaborative

coordination of patient work-up and treatment ... '-"' ....1">"'. . ."'. was
autonomy for the DNP student in ordering laboratory
and responding to testing

was

two half days per week in addition to the

nn""""~,

month. Fortunately,
physician DralctJc~ed in the clinic area weekdays managing infectious '."'''''''<4""
was available to view the laboratory results of
to the clinic.

were
'-'v'vu...............'....

project.

as

communication efforts improved steadily over the course

included 1'"P1",>,.,.<> notification, incoming telephone
80

Ull:':l:l<:lgl;;:l,

"',""YU'

"""'",VA ..

faxed pharmaceutical

appointments,

res;pons€~s

available by cell phone and responded to emails on days
ambulatory clinic

The DNP

was

was not in the

The

nurse helped to coordinate HCV clinic
of staff <A"~""''''''',,,, should have

student. In retlroS1Dec:t. this

project to ensure a smooth

throughout

':J<YU'-'"U

"'....,.... 114

not be secured by

encouraged

ambulatory

time of

should

completion.

Implications
The

of the

of this

preparedness

HCV volume

model in

1 U "..... " ' . ,

communities will require motivated, passionate

included a thorough literature

HCV 1Tp",'tn1P""'t· completion

a Community

concerns; development and implementation

Assessment to assess provider
community-based

this project can be applied to other

project ex(:ee(leC1 two years
of care

a West H,...''"'U1f'»....'''. community

time and """,,,,.,.,,, to HCV program development. In sum,

individuals who can dedicate
time period

The

U\;;\,QU'I:'.

the new HCV screening recommendations

model of care and processes
Using

review on

C dilemma will be at its e:reate;st this

increased

for the presumed increase
are enacted.

""'I,,""'lH'"

and early

treatment

a

treatment .......r'rrr"'rn evaluation.

Practice
Involvement of a Doctor of Nursing Practice Student
process of establishing a
HCV treatment involved the coordination
the first

project

literature on HCV models

ua,,1V1.,

multidisciplinary approach to
several members

a healthcare team.

the DNP student thoroughly reviewed current
to treatment. An analysis of

care and
81

infonnation was guided by incorporating components of the Chronic

a ",£u"nn,"p ...

to

,~n"'''p

Model in
''''''~'''1V'U'''' for

care with the

improved outcomes.
DNP student was

liaison between administrative
and

partners,

steering
1-''''' ...........

the clinic support staff. In collaboration with the
physician, the HCV treatment programming was developed and
student provided HCV educational services to
to the

1-''''''''''''''''

disease

manager on

clinic referral .,,.."•., ..

referred to the clinic and provided
student

estimated community

HCV treatment regimens; and anticipated

responsibilities of a nurse practitioner to coordinate HCV treatment
",,,,>AVA>

The DNP

U,","'v,",.

in HCV treatment regimens. The

provided infonnation to

and their

was used to secure a temporary

This

oos:mcln at the

completion

(Appendix R).

Community Involvement
project allowed
collaborate and improve care

.",,,,,,.,-,'uu.,,,, from a variety

services to

patients with a chronic health

West

This multidisciplinary approach to improving care for individuals with
hepatitis C focused on the addressing common
the

healthcare

to successful treatment.
•...,,,,,,,.v'u,,,.;> from

nursmg,

administration, pharmacy, mental health and ","""'V"V" servIces, vv"u.........J agencies,
public "V,,,,,,,, and finance.

efforts in this community may offer

'''V''b'''~

improvement initiatives.

attempting to ",.''''''J1'''U similar
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to other

Education
this project, the DNP ,,, ........ ,,"
as outlined by the American
Association

(AACN) in the Essentials of Doctoral Education for

Advanced

2006). The core competencies focused on nnrn<lM
scholarship, education, innovation, clinician, and

advocacy.
this

to effectively treat individuals with hepatitis C in

~~ •• .u.HUJ.u.

to bring stakeholders together and present
as it existed. Translating current research into practice was

magnitude
accomplished by

itA,""f1,,,.A

and adapting guidelines in the development of

protocols for treatment. Advocating for appropriate clinic staffing and strong educational
components to

clinic programming was imperative. The potential impact

project

additional DNP practice innovations from this clinical site or

OP''lpr<ltp

this

In

Policy
occurred during a time when the impact of
"''''''70r!

across the

In 2010, the State of Michigan Hepatitis C
investigation reviewing the dilemma

rec:ontlmenClatlOils for greater screening, DfI::venWJn.
of

treatment

C continues to expand,
to decide how personnel and

chronic illness.

83

H U ........J

........

resources are

to Macrosystem
project addressed improving care for
level. The efforts put forth during the
scu.sSH)nSOnCOJllat)Or;atl()n with

Qualified Health

partnership
treatment

community practices and, +h"" ...,+"...,.

A ...... AY~l1

.. V

.... "'TlI£1

to a DOlten1UaJ ma,Cf()svstem level.

31,2012 yet another meeting was held in this ""'.,, ........... y to SPt,C111Cal1
bring local ___ ,,.._ ...__ C treating providers together to discuss the challenges
the

HCV treatment and the workload
treatment. The meeting was attended by the DNP student, a family nurse
disease physicians, the medical director of the

who

a gastroenterologist, and two physician
onveI'sal1orls "",,,y.,,,,",u on

to manage the increasing number of referrals

and treatment and how the age-based screening might
.""F;u'V'Jv .....

",",<LLH;''''

current

with the virus, The

individuals with

HCV prohibits

Treatment monitoring stnlteJl:les
as viable options to increase case loads.

case

..,.\,;'UH,.VIIUH

this community may be augmented by
use of Doximity, an on-line network established to allow
the ""''''''',''1I''1"11n

to

A specific hepatitis C treatment group
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for

providers in this community to u""" ....;>.:> challenges in HCV

eventually, case study review is

l.I!<lJ.lll',",U.

Care Act
At

time of project completion, the clinic had not yet received a single referral

a ",,,"'O~'T who lacked healthcare insurance.
I-'U"U.U\"'H~,

C is prevalent in

it is likely that

with mental illness, drug and/or

not yet been <l('rpPtlPt1 or U''''I5H'V':>\.,Y
"'Tn",. Court uphold the decision to mandate

accordance

l ......

lJ"'lC1P~l1'

Protection and Affordable

:-"P.,.Vl("f'<l

2010) for all US

2010 (US Department of Health &

I'.h'7o",

1.I",",'I.I,v

will flood the healthcare

",,,,,,,r,,,",, with the potential to diagnose higher numbers of people with hepatitis C. The

improved preparedness of this community to care for current and increasing numbers of
with hepatitis C shows dedication to

community in

serious healthcare system
nrl""Plnt

time the outcomes

are unknown.

healthcare relative to hepatitis C

occur regardless of whether
C screening

Act passes or fails. Impacts
F'.

"""'V.lA"',,;) are pending and will require

V . . ,,,"VA",,,

of service delivery. How we advocate
............

u.,~

a critical question for healthcare

as a
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evaluation of optimal
or increase access to the
and the healthcare industry

Sustainability
From the initiation of the
of

community need to

institutional leaders had a clear understanding
the inadequate care for individuals with

Healthcare institutions have responsibilities to
therefore

u""...",,,,,

welfare

as a community

this

the

radiology services,
have

H U. . ." ' ...

hospital pharmaceuticals services. Prescription

pharmaceutical companies offer generous

high deductibles and patient a.':'~'l':''''Ul\,'''

opportunities for those
with

provider

covered the cost of medications with submission of prior

OPn,Pr<>

authorization documentation.

for

and

initiative. Financial

considerations for the hepatitis C clinic included billable services
laboratory

C.

resources. Available grant opportunities

are available
be sought using the

preliminary data of patient volume, anticipated personnel required to manage case loads,
projected

UH...... "~ .... .,

to

community-based hepatitis C clinic.

AU"U"C;"

Future Research
The implementation of this community-based HCY treatment clinic generated the
possibilities for

and practice innovation projects.

benefits of individuals with
rates of successful treatment may
""'I.""''''

project

outcomes

this community

U"'~U"H

in monitoring laboratory

monitoring may be augmented with

a support

and

to increased numbers of local support groups.
include

evaluation

collaborative efforts between a DNP prepared
Lastly, one of

time

C participating

example, a study

HCY treatment
practice nurse and

biggest challenges in treating hepatitis Cis
''''",.J.UF,

use

Improvements in the efficiencies of
electronic registries
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management of

This would

an exceptional

VHU''"'V'''F.'"'

setting where

in this

documentation still exists (Appendix S).
Future of Nursing
Adopting structural changes in education and supporting terminal
nursing ......""?,,~"" is in line with
Institute

Medicine (10M, 2011) on

Health.
U.4UV . . .' U

recommendation

key messa.ges

forth by

Future ofNursing, Leading Change, Advancing

are poised to have a greater impact on the direct
healthcare.

np{lrpl~<!

indirect

educating clinical and administrative nurses with the highest

level of education and

of implementation science

their

rigorous academic requirements, improved
Additionally, collaborative
healthcare professionals

u'-'<uu • ..., .....

outcomes at

costs are

between nurses, physicians,

be encouraged and will hopefully lead to

healthcare ,",V"""•.;) and improved

other
VHClLHr,'.'"

outcomes.
Summary

C is a major international
populations who
included an assessment

This hepatitis C initiative

from other
community

occurs frequently

dilemma

development and implementation

''-'V-11'''''''''''.1 hepatitis C treatment program; evaluation

progrrurnm,mg by

health pel:ceIPW)nS pertaining to barriers to

and

nrr'''"1PFl

early

outcome evaluation. The community-based hepatitis C treatment clinic was
with collaborative efforts by
V.L~,"''''JlVUa..t.,

Hv • .lHJj,,,UJ."

and community

providers, institutional

generating a multidisciplinary approach to "'"'If'..... "
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...'

C care.

conceptual

framework of the Chronic
eOllCaUOJn, support, and

Western Michigan

this project will
for the impending impact

implementation of

.... ""·I"PlnTll'"<!

programming on patient

between

long term outcomes

care for their

Model helped to focus

the preparedness
hepatitis C this decade.

C clinic allowed community providers access
1-'. . . . "' .......

of individuals

early program evaluation showed improved health

C.
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Appendices

Appendix A
Chronic Care Model

Chronic Care Model

The Chronic Care Model

Resources and Policies
Se]fManagement
Support

Delivery
System
Design

Proactive
Practice Team

Patient

Improved Outcomes
nc><I"",-d by The MacC",lIln.1il\J1>:
ll.' ,\C1'· ASfM JournaL. and lIook.

From "Chronic Disease Management: What Will It Take to Improve Care for Chronic
Illness?" Wagner, E. H. 1998, Effective Clinical Practice, 1. Reprinted with permission
(Appendix B)
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Physicians Copyright

American

of Physicians Copyright Permission

ACP

J.

U""'''.l''l'l'''1

CoLLEGE OF I-'uvc,,"',

INTERNAL MEDICINE

I Doctors

WAECP121
June

12

State
1 Campus
Allendale, MI 49401-9403
Dear

Leigh;

Thank you for your request to print (dissertation)

following from

TUh"""'"

Clinical

I-'>'",r","o

1, Effective Clinical
1998, Vol1, Chronic Disease Management: What Will It Take
Care for Chronic Illness? Wagner EH

rnn,rr'l\,''''

Permission is granted to print
preceding material with the understanding that you will
appropriate credit to Effective Clinical Practice as
original source of the material. Any
of Physicians is not
version must carry a disclaimer
that the American
the accuracy
translation.
permission grants non-exclusive, worldwide
edition in print
for not
profit only.
not grant permission
entire articles or
unless explicit
is given.
letter represents the agreement between ACP and Elaine Leigh, MSN, FNP-BC for request
17568 and
all prior terms
the requestor.
Thank you for your interest in Annals ofInternal Medicine. If you have any further
or
would
to discuss the matter further, please contact me at
or fax 856-489-4449.

Coordinator
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Appendix C
Multidisciplinary Model of

for Hepatitis C

Multidisciplinary Model of Care for Hepatitis C

Institution
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Hepatitis C Initiative Introductory Letter

Hepatitis C Initiative Introductory Letter
2011

February
Colleague(s),

you know:

Hepatitis C (HCV) is the most common blood-borne infection in the United
States and is the leading cause of liver disease according to
National
Institutes of Health.
The Centers of Disease Control and prevention estimates that 3.2 million people
are affected with HCV within the US. The number of new cases is declining,
but the total number of deaths is expected to rise in the next 20 years due to
prevalent cases with long-standing infection.
Chronic hepatitis C accountsfor 8,000-10,000 deaths per year.
Over 700 Chronic Hepatitis C cases have been reported to the Muskegon
County Health Department since 2006.
to announce a new community healthcare
A
with support of community leaders to improve the care
is
forward through collaborative
This
doctoral student
on the development a multidisciplinary hepatitis C
treatment program. Ms Leigh is currently completing
Doctoral of Nursing Practice
(DNP) at Grand Valley State University and brings years
gastroenterology and hepatitis treatment. Her
to
assist
those with
a sustainable program
access to treatment
hepatitis C.
,.H"'",,"''-'

Barriers to treatment will be modified by
partners practice. Psychological
case management, pharmaceutical support, patient education
support
included
programs will
We
your help. Assessing your opinion of the magnitude of
issue will assist in
early project development. You are encouraged to complete the survey by clicking on
the link or copy and paste the address into your web browser to Survey Monkey by
March 11,2011.

All information will
names of providers and practices
from your area.
Thank

In

<;>r1,'g.Yu.....

we are collecting
bottom the
to ensure we collect an appropriate representative

for your support

initiative.
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Appendix E
C Needs

Hepatitis C

Assessment

Thank you for your willingness to
this
It is important that each provider in
the practice fill out a ror,,,r,,.,1-L> survey.
Please answer the questions in numerical order
Please identify specific barriers you have encountered in getting your patients referred for

1. How many hepatitis C patients have you
assessed/diagnosed in the last

o
o

o
o
o

O-S
6-10
11-20
21-30
>30

2. How
are you to
a routine patient about
a history of intravenous (IV) drug use?
o
likely
o Likely
IJ
Somewhat likely
o Never
3. How
should
o Very likely
o likely
Somewhat likely
o Unlikely

o

4. How likely are you to ask a routine patient about
a history of blood transfusion?
likely

o

o
o

Somewhat likely
Unlikely

hepatitis C
Name

person who

the

Name
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S. How likely are you to
profile should they
blood transfusion?
o Very likely
o likely
o Somewhat likely
o Unlikely

a hepatitis
history of

6. How likely are you to
hepatitis C ,. ..""',.nn""n

a patient

o

Very Likely
o Likely
o Somewhat unlikely
o Unlikely
7. How likely are you to encounter
barriers in getting your patients referred
C t"rO:l1"YY,,,,

o

Very likely
Likely
Somewhat
o Unlikely
8. How likely is it for you to refer patients
to a dedicated, multidisciplinary hepatitis
C treatment clinic in Muskegon?
Very likely
o likely
o Somewhat likely
o Unlikely

o
o

Appendix F
Hepatitis C Initiative Stakeholder Meeting Invitation

Hepatitis C Initiative Stakeholder Meeting Invitation

April 1,2011

to ask you to participate in a collaborative community healthcare initiative to
I am
C.
are developing a
improve outcomes and
patients
mUltidisciplinary treatment program to better serve patients in our area and we are seeking your
opinion. As you
there are numerous biopsychosocial
caring
people with hepatitis and treatment programs can be labor
for the patient and
healthcare providers.
program
two specific goals.
to
access to treatment
and also to improve therapy outcomes
instituting a collaborative evidenced-based
magnitude
health
We are developing a taskforce of professionals to further discuss
of a recent Hepatitis C
dilemma posed by hepatitis C in our community by reviewing
Needs Assessment from primary care providers in our area. Ultimately we are
individuals who are interested in assisting with the coordination of services to better serve
C.
interested in
part of this program development or
patients with
overall feedback or comments
this
please join us at 7:00am on Friday April
2011 (location undisclosed).
Thank you in advance for your support of this community healthcare initiative.
Respectfully Submitted,
Committee
Hepatitis C Initiative
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Appendix
Multidisciplinary Partnerships

Multidisciplinary Partnerships
Multidisciplinary
Partner

Infectious Disease
Physician

Care Provider

Institutional!
Community
Referral

Reason For Consultation

Continuation of Care

Institutional

Provides the initial health
assessment, orders
pretreatment laboratory studies, and
HCY education.
Determines
for physician
consultation.

Institutional

Provides final clearance for patient
to initiate
C treatment.
This will
evaluation of all
pretreatment
and referral
consultations.
Provides on-going healthcare
management of individual's
health and chronic illnesses.
Psychological evaluation for
stability of mental illness

APN will
ongoing management of
hepatitis C treatment once
patient is deemed
for treatment
RN will
ongoing
of medication
side effects and laboratory
schedules.
Collaboration with APN
on treatment progress.

Community

Community
Psychological

Pharmaceutical Support

Social Work/Case
management

Both

Community

Evaluation of ocular and visual
stability,
for those with

Ophthalmologist!

GynecologicalJ
Obstetrician

Radiologist!
Pathologist

Evaluation for onI2-to~ar
patient assistance
programs, authorization
requirements, and educational
materials
Evaluation for health insurance or
financial barriers to
treatment

Community

Institutional

Community

Contraception Management
(Ribavirin is a Pregnancy category 3
which
females to adhere to
sex practices
estro en forms
Provides and evaluates liver imaging
and liver
These results
determine the course of
treatment
Evaluation for stability of history of
coronary artery disease or kidney
disease
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Col.laboration with HCY
treatment team to manage
medication side effects
For moderate to severe
mental illness, continuous

documentation

trans
Follow up care
for any visual
durin treatment
pregnancy tests
for all female patient on
treatment who are
of reproduction

exams as necessary

May require pretreatment
electrocardiogram gram
and/or echocardio ram

Appendix H
Informed Consent

Infonned Consent

Study Title: Evaluation of a Community-Based Hepatitis C Treatment Program
Program Evaluator: Elaine A. Leigh
Introduction
You have been asked for pennission to look at your medical record. Before you decide
to agree or not agree, or not to volunteer, we want you to know as much as possible about
this project. The U. S. federal government expects us to provide this infonned consent
paper to you and you will be asked to sign it. Please read it carefully and talk to the
investigator, Elaine A. Leigh, if you have any questions about the study. You may also
want to talk about it with your family or friends.
There are general ideas that apply to all project involving people done at Mercy Health
Partners:
1. Taking part in the project is entirely up to you. This means that you do not
have to be involved in the project if you don't want to.
2. If you agree to give consent for us the review your medical record, and then
change your mind, you can ask us to stop. There is no penalty for this.
3. You may not gain any benefit in taking part in the project. However, we may
learn more about hepatitis C treatment programs from you, and this may help
others in the future.

Has this project been approved by the hospital?
Yes. The project has been reviewed and approved by the IRB at Mercy Health Partners.
The members of the IRB are physicians, other healthcare professionals and community
members. They volunteer their time and expertise in reviewing all projects done at Mercy
Health Partners. Because the program evaluator is a graduate student, Grand Valley State
University's Human Research Review Committee (HRRC) has also approved the study.
Why was I asked to be included in this project?
You were asked to be in the project because you have been evaluated at the hepatitis C
clinic. We are asking all patients who have been seen at the clinic between October 1,
2001 and March 15, 2012 for consent to look at their medical records since they have
been at the clinic.
What is the purpose of the project?
The purpose of this project is to complete an initial program evaluation of the hepatitis C
treatment program started at Hackley Hospital in Muskegon Michigan.
What do I have to do to be part of the project?
This project requires your pennission to review your medical records. Once you have
read the consent, had your questions answered, you will be asked to sign this from.
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What is the duration of the project?
When
data has
collected
reported from those patients who
consent, the
complete.

their

What are the risks and discomforts?
There are no known health risks for those who
to
in this project. To keep your
data private, it will be copied to another form without your name, address, or
personal information that could identify you.
What are the benefits of being part of this project?
There are no known
to you
being a part of this project, but clinic
and
nurses will learn more about
services they
to you. It may help them find out if
the hepatitis C treatment program is meeting patients' needs. This information may
shared with other nurses and doctors
programs like this one.
What are my rights and responsibilities?
if you agree to give access to your medical records
to have your information removed later by calling

this project, you may
evaluator,

Who wiU see my records and how will they be kept confidential?
Only those people who work on the project will see any record
could identify you.
No one will give out
name or personal information. Information you
us will
added to information from other people the project before it is reported in public. No
public reports will use your name, address, or other personal data that could be linked to
you. You will
to
Portability and Accountability Act
(HIPAA) form with your
consent to allow the program
to review your
information. A
will be used to further protect your data.
Also, as part of routine
projects, members
of the Mercy Health
.,."'Tr"A'"" Institutional Review Board (IRB)
contact you about your experience with
this study.
What are
financial responsibilities?
is no monetary
or cost for

of this

nrr\1 ".,~t

If I take part in this project, can I also participate in other project/studies?
''''H_~U.'''' to take part
this project does not
you joining other
If I don't want to be in the project any more, what should I do?
You are
to leave the project at any time.
decide to leave the project, there is no
penalty. If you decide to leave the project, all you have to do is contact the program
evaluator listed at the
of this

Could I be taken out of the project even if I want to continue to participate?
are some reasons why you could be taken out of the project, although
unlikely, the project for some reason could be suspended or cancelled.
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Who can I contact for more information about this project?
The names and contact information
program
IS
contact her if
want to:
411
more questions
411
Obtain more information about
project
411
Discuss
concerns
project you
have
411
Stop participating
before it is finished

You

A. Leigh, MSN, FNP-BC

Hepatitis C Program Evaluator
Student
Doctor of Nursing
State University
Grand
301 Michigan St.
Rapids, MI 49503
(616) 331-5694
Who else can I contact if I have any concerns about the study?
Ruth
Brintnall,
AOCN, CHPN, APRN-BC
Student Advisor
Kirkhof College of Nursing
Valley
University
301 au''-''li/:;, ......
NE,
.. ,.....v,'"'" MI 49503
(616) 331-3338
If you
any questions about your
as a partICIpant this project
contact:
Valley State University Human ",."".,""..... Review Committee at (616) 331-3197.
Health
Institutional Review
at (231) 672-3941.

I understand that by agreeing to
in this
I am responsible for informing
the program evaluator of any concerns.
I have had a chance to ask questions about the project and was given enough time to
make a decision about being part of the project. I have talked to as many
as I
need to
me make
decision. I understand that my participation is voluntary. I
have
a copy this form
willingly agree to participate in
project.

Signature

Witness

U'5HUL.u
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Appendix I
Health Perception Survey

Health

~P'·""Pl... hr\n

Directions: In order to best meet your needs, please respond to each of the following statements
two weeks. Knowing
marking an (X) on the Line that best corresponds to your educational needs in the
your needs will assist clinic staff in offering appropriate resources as you complete treatment for hepatitis
C.
==~::;.:. How well do you understand the disease of hepatitis C?
an (X) near the VERY
LITILE would indicate you do not understand the disease of hepatitis C. You can mark the line anywhere
along the line.
place an eX) on the line below each statement to identify
When thinking about the past two
the degree to which you:

I L Felt in control over the management of your hepatitis e
I

I

5~

10
VERY
LITTLE

SOMEWHAT

I

100~
VERY
MUCH

2. Had appropriate resources to manage your h .•""d'+" e
1

I
!

0
VERY
LITTLE
3. Had adequate psychological/emotional support

I

I

I

I

50%
SOMEWHAT

I

I

I
0

I
50%
SOMEWHAT

VERY
LITTLE
4. Felt supported in making decisions about your hepatitis e care
I

I
10

I

50%
VERY
SOMEWHAT
LITTLE
5. Understood what is expected of you in managing your hepatitis e
I
I
10
VERY
LITTLE
6. Had confidence in

5~%

SOMEWHAT
to follow a HeV treatment plan

99

100%
VERY
MUCH

J

I

100%
VERY
MUCH
I

I
100%
VERY
MUCH
I

I
VERY
MUCH

OOt:nOllX

J

Patient Information Handout

Patient Infonnation Handout

the
You are here to
treatment for hepatitis
We
developed a
to
you the
treatment. Many of you may
know
treatment for hepatitis C can be challenging but we are here to support
Be
treatment. We carefully
aware that not everyone who is evaluated will eligible
detennine treatment eligibility on a one-to-one basis as everyone
a different
background.
nn\HT'''Tn

of our new program we are
you to complete a
short
at
beginning of some of
visits to
clinic.
program is focused on providing you
with the
education and support to
your
while you are going through
treatment. The survey questions allow us to detennine which areas we can provide
further
to you.
You will not be required to write anything; however, you will be asked to simply
of your medical
an "X" when answering the questions. Your surveys will remain as
record and therefore confidentiaL
Hepatitis C
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AppendixK
Informed Consent Narrative

Informed Consent Narrative

and I am a part of the office team here at
hepatitis clinic. I
My name is
would
to invite
to
a study we are doing at
clinic to evaluate our
~ ...."_..". We want to learn more about our patients who are enrolled at
clinic
including
think about common
that may impact your treatment. We are
inviting all
who come to the clinic. Is it okay I continue?
benefit directly from
First,
participation is voluntary. You will not
participating in
study but what is learned may help you or someone
study
will not require any additional work from
The study will use information already
your medical
like
surveys
have completed already.
it will
that
us your permission to allow an investigator, who is a Doctor of Nursing
Practice student at
to access your medical records. The investigator will collect
C, and
county of residence.
information such as your
your type of
Your name will not
or used anywhere ... as a matter of
your
will be
as it is collected to fully protect you.
will
an opportunity to ask
me
and you can call the investigator I cannot answer your questions. We
want you to
your consent carefully
you decide.
consent will have
addition information about the study. Do you have
now?
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Appendix L
Institutional

Board

Valley

University

@)
GRANDVALLEY
SrATElJNJvERSITY.
www.gv>o.edu

DATE:

February 15. 2012

TO:
FROM:
STUDY TITLE:
REFERENCE #:
SUBMISSION TYPE:

"'Iaine Leigh, MSN
Grand Valley State University Human Research Review Committee
[282940-2] Evaluation of a Community-Based Hepatitis C Treatment Program
12-82-H
Revision

ACTION:
EFFECTIVE DATE:
REVIEW TYPE:

APPROVED
February 15, 2012
Exempt Review

Thank you for your submlsslon of materials for thi$ research study. The Human Research Review
Committee has reviewed your submission and approved your research plan application under Exempt
review. category 1-2 and 1-4. This approval is based on no greater than minimal risk to research
participants. All research must be conducted in accordance with this approved submission.

Pleas. insert the following sentence into your Information/coosent documents as appropriate. All
project materials produced for participants or the public must contain this information.
Th/$ EXEMPT research protocol has been approved by the Human Research Review
Committee at Grand Valley State University. FUe No. 12-82-H.
Exempt protocols do not reqvira formal renewal. However, we do confirm on an annual basis that the
research continues to meet the criteria for exemption and that there have been no signiflCBllt changes
in activity or key personnel. By February 15, 2013. please complete the brief C<>ntinulng Review
AppliCJItion Fenn. available In your IRaNet Project Designer, or from our website, ~. gvsu . ed ufhrrc.
and submit this form via IRaNet.
Once study enrollment and data analysis have been conduded, please complete the Closed Protocol
Reporting Fonn on our website, and upload a saved copy to IRaNel.
This project remains subject to the research ethics standards of HRRC policies and procedures pertaining
to exempt studies.
Please note the following in order to comply with federal regulations and HRRC poUcy:
1. Any revision to previously approved materials must be approved by this office prior to initiation.
Please use the Change in Protocol forms for this procedure. This includes. but is not limited to.
changes in key personnel, study location, participant selection process, etc.
2. All UNEXPECTED PROBLEMS and SERIOUS ADVERSE EVENTS to participants or other parties
affected by the research must be reported to this office within two days of the event occurrence.
Please use the UP/SAE Report form.

- 1-
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3. All instances of non-<:Oll1pjiance or complaints regarding tIlis study must be reported to tIlis office in
a timely manner. There are no specifIC fonns for this report type.

It you have any questions, please contact the HRRC Office, Monday through Thursday, at (616) 331-3197
orhrrc@qvsu.edu. The office observes all university hondays, and does not process applications during
exam week or between academic !eons. Please include your study title and reference number in aU
correspondence with tIlis office.

cc:

- 2-
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Appendix M
Institutional Review Board Mercy Health Partners

(f,

MERCY HEALTH PARTNERS

February 16, 2012
Elaine A. Leigh MSN, FNP-BC
15306 Forest Park Dr.
Grand Haven, M149417
Dear Ms. Leigh,
The MHP IRB has reviewed your project entitled, Evaluation of a
Community-Based Hepatitis C Treatment Program. Specifically the following
documents were reviewed:
•
•
•
•

Written plan for the evaluation
Hepatitis C Treatment Program Evaluation Tool.
Informed Consent Narrative
Informed Consent Document

This project is exempt from IRB oversight, based on a design which
involves a retrospective review of existing data, and a plan for securing protected
health information. Further reports to the MHP IRB are not required.
Thank you for your submisSion, and please contact me if you have any
questions or concerns.

Kathleen Thomas, RN, MSN
MHP IRB Representative

~SHoke ,....u~:
: ~•.•:.; ·:'M?RCY·cAMpus;: ";.:.:::, '~:. ;~iJ~;~;~~ c.yd~~. ';..
...--..V. . .•..•...••
•••
i SOO:E. s..eUnan BNd. ' P.O. eo. sis .:;• •l7ail.00Jc ~, p.e. ~ J SS '
n .! . stot9,Street · ,"

f.

Shelby, MI 4 91.S5
23 1.86 1.21 !l<i

MI4 9443.~~·
23l.\S72.2000 . (600) S63.41 ~5 Mo$lo>gon.

"
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AppendixN
Hepatitis C Treatment

....... '....."',.. Tool

Hepatitis C Treatment Program Evaluation Tool
_ _ _ _ (Patient Code)
DemographicsiHistory
Birth date/age

Genotype

Treatment history

lor 4/2 or 3

Naive/Partial Responder/Relapser

Gender

Residential County

Community Referral: Yes/No
Agency:

Male/Female

In the previous
2 weeks have:
2mm=l%

Date
(8aseline/educa
tion session)

Hea lth Perceptlon Survey
Date
Date
(Consultation)
(Start of
Treatment)

Date
(First follow up)

Date
(Second
follow up)

Question I

Felt in control over the
management of your
hepatitis e

-

mm=_%

-

mm=

%

-

mm=_%

-

mm=_%

-

mm=_%

-

mm=_%

-

mm=

%

-

mm=_%

-

mm=

%

-

mm=_%

-

mm=

%

mm=_%

-

mm=_%

mm=

%

-

mm=_%

-

mm=

%

-

mm=_%

-

mm=_%

mm=_%

-

mm=_%

mm=_%

-

mm=

-

mm=_%

-

mm=_%

-

mm=_%

mm=_%

-

mm=

-

mm=_%

Question 2

Had appropriate
resources to manage
your hepatitis e
Question 3
-

-

Had adequate
psychologicall
emotional support
Question 4
Felt supported in
making decisions
about your hepatitis
care
Question 5

-

e

-

%

Understood what is
expected of you in
managing your
hepatitis e
Question 6

-

mm=_%

-

mm=_%

Had confidence in
yourself to follow a
HeV treatment plan
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Appendix 0
C

and Correspondences

Hepatitis C Clinic Documentation and Correspondence
Hepatitis C Pretesting Requirements

Date

Test
Hepatitis C Genotype

VIRAL LOAD
CBC w/Diff

CMP

TSH

Normal

Results

Undetected
3.8-10.8
12-16/37-47
150-450
74-106
7-20/0.7-1.2
15-46/15-46
0.47-4.68

Uric acid

2.5-6.6

Triglycerides

5-150

Iron studies

37-170
265-497
15-50
6.2-264
11-13sec

Protime/INR
Pregnancy (when applicable)
Anti Nuclear Antibody (ANA)
Anti Smooth Muscle Antibody
(ASMA)

Neg
Neg

Ceruloplasmin
Alphafetoprotein (AFP)
Hepatitis B surface antibody
(HBVsAB)

16-45.0
<6.0
Absent

Hepatitis A antibodies (HAVAB)
HIV 1/2

Neg
Neg

Eye exam
EKG (when application)
Imaging (CT, Ultrasound)
Liver biopsy
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WBC
HGB/HCT
PLT
GLU
BUN/CR
AST/ALT

Serum Iron
TIBC
%Sat
Ferritin

Hepatitis C Clinic Intake Assessment

Name:
Birth date:
Pharmacy:
State:

Support person phone:

Past

YIN
Approx

DM

of diagnosis:

YIN
YIN

CAD

HCVRNA:

YIN
Liver

YIN

COPD

YIN

Other(s):

Previously treated:
Tolerated?
Medication list
Imaging:

LastE eExam:

YIN

YIN

Alcohol:

YIN

Bipolar

YIN

Recreational

YIN

Schizophrenia

YIN

Tobacco:

YIN

Currently medicated

YIN

counseling

YIN

Suicidal thoughts/attempts
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use:

Risk factors
use

YIN IV
YIN Blood

Con trace tion
YIN Sterilization procedure:
Hysterectomy(fubruligation/Vasectomy

before 1992

YIN
YIN Tattoo,
i

YIN
wlHCV

exposure to someone

Regular menstrual cycles
LMP:
Current birth control:

YIN

Menopause

LMP:

YIN

Social
YIN Married
Lives with:
Working hours:

YIN

Vaccinations
Hepatitis B Virus (HBV)

YIN

Hepatitis A Virus (HA V)

Sleeping

Seasonal

YIN

Source of support:

Relative Contraindication
YIN

Absolute Contraindication

< 10, ANC <1000, PLTs<50

YIN
YIN
YIN

Pneumonia

Hemodialysis

Uncontrolled, active, major psychiatric

<50

Substance and alcohol use
(encephalopathy, coagulopathy, ascites)

YIN

Anticipated Poor compliance

YIN

Untreated mental health disorder

YIN

Stable auto-immune disease

YIN

Thalassemia and sickle

YIN

Sarcoidosis

YIN
(DM,

anemia

For HIV co-infected:
CD4<200 or
Concurrent use if Zidovudine
(ZDV)

uncontrolled medical disease
TB, Cancer)
CAD,

YIN

Untreated thyroid disease

YIN

Pregnancy, nursing, child-bearing potential
(anticipated
no birth control)

YIN

Active,

YIN

HIV co-infected
Advanced uncontrolled HIV (CD4
<100)
use
"'Ull"""',,, (ddl)

i
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autoimmune disease

Clinical Presentation
Symptoms:

Signs:
Skin:
YIN Spider angiomas
YIN Porpheria cutanea tarda

YIN

Asymptomatic

YIN

Fatigue

YIN

Anorexia

YIN

Myalgia

YIN

Arthalgias

YIN

Asthenia

YIN

Weight loss (except where ascites)

Stigmata of cirrhosis:
YIN Mild jaundice
YIN Hepatomegaly
YIN Splenomegaly
YIN Peripheral edema
YIN Hemorrhoids
End Stage Liver Disease (Decompensated)
YIN Ascites
YIN Encephalopathy
YIN Coagulopathy (PT >3sec; INR > 1.3)
YIN Varices (bleeding or non-bleeding)

Childs- Pugh
The score employs five clinical measures of liver disease. Each measure is scored 1-3, with 3 indicating
most severe derangement.

Measure

1

2 points

point

..

"

3 points ,

Total bilirubin, Jlmolll
(mgldl)

<34
«2)

34-50 (2-3)

>50 (>3)

Serum albumin, gil

>35

28-35

<28

PTlNR

<1.7

l.71-2.20

> 2.20

Ascites

None

Mild

Severe

None

Grade I-II (or suppressed
with medication)

Grade IIIIV
(or
refractory)

Hepatic
encephalopathy
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Patient Valu
Date

-

"

HEPATITIS C THERAPY CONSENT
Contraception
D

For patients receiving pegylated interferonlribavirinltelaprevir (Incivek) therapy

_ _ _ _ _ _ _ _ _ _ _ _ am aware that ribavirin, one of the oral components of Hepatitis C
therapy, can cause birth defects. Defects can be caused if either the mother or the father is using this
medication.
•

I realize if I become pregnant, or impregnate someone, the resulting child could have
birth defects.
•
I agree to use two forms of birth control during my therapy and for 6 months
afteIVIards.
•
If I am female, I may be required to obtain negative pregnancy test prior to starting
therapy.
•
If I am female I may be required to submit to monthly pregnancy tests for the duration of
my therapy and for six months after therapy is fmished.
•
I agree to advise the clinic if either I or my partner fail to use appropriate contraceptive or
suspect a pregnancy may have occurred despite the use of contraceptives. I understand
that oral contraceptive may not be as effective while I am on treatment.
Some examples of non-hormonal forms of birth control are: a male condom with spermicidal jelly or
female condom with spermicidal jelly; a diaphragm with spermicidal jelly, a cervical cap with spermicidal
jelly, or an intrauterine device (IUD).
___(patient initials)

D

For patients receiving pegylated interferonlribavirin therapy

_ _ _ _ _ _ _ _ _ _ _ _ am aware that ribavirin, the oral component of Hepatitis C therapy, can
cause birth defects. Defects can be caused if either the mother or the father is using this medication.
•
•
•
•
•

I realize if I become pregnant, or impregnate someone, the resulting child could have
birth defects.
I agree to use two forms of birth control during my therapy and for 6 months
afteIVIards.
If I am female, I may be required to obtain negative pregnancy test prior to starting
therapy.
If I am female I may be required to submit to monthly pregnancy tests for the duration of
my therapy and for six months after therapy is fmished.
I agree to advise the clinic if either I or my partner fail to use appropriate contraceptive or
suspect a pregnancy may have occurred despite the use of contraceptives. I understand
that oral contraceptive may not be as effective while I am on treatment.
___(patient initials)
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•
•
•
•
•

I understand Hepatitis C therapy can have side effects such as rlpr,,·poo'
I agree to notify my
immediately have symptoms of severe aeiDreSSI'OI or suicidal
",,,.....F,,,,,, or plans.
At the
time, I do ( ), do not ( ), have a history or current =rnnT{\m
de[)re1;sicm or
psychiatric disorders.
If I have a history of depression or any psychiatric disorders, I may be required to have clearance
by my
for treatment
If I have a history of depression or any psychiatric
I may be required to be monitored by
my
the entire treatment.

•

I understand that
C therapy can cause a decrease in certain blood
reason, frequent blood tests will be necessary.

•

I understand the importance of:
o Regularly scheduled appointments
o Blood work needs to be done in a timely manner and when requested
o Monthly pregnancy test (where applicable)
o
the medication as
o Reporting any ;:'''/'',5''''''''' V"~U'E>'N in my medications by any provider
I understand that my treatment may be cancelled ifl do not comply with these

•

and for this

initials)
I have been informed or and understand the risks and benefits of Hepatitis C therapy. I hereby request to
Hepatitis C therapy.
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Hepatitis C Clinic Referral

Whom it May Concern,
This note is to
you know we have received a written referral from your healthcare
provider for you to be seen at the hepatitis C treatment clinic.
this time, we are
processing referrals and scheduling appointments but because ofthe complexity of
treatment we have a limited number of people we can see. We will be contacting you for
an
when we are
We encourage you be as educated as possible about hepatitis C before your appointment.
Additional education materials will be given to you when you are seen but in the
meantime a good website for gaining infonnation

We appreciate your patience,
Hepatitis C Treatment Team
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Medication Reconciliation

Date
Reviewed

Medications

Needs
Reconciliation

Date Reconciled

YIN
YIN
YIN
YIN
YIN
YIN
YIN
YIN
YIN
YIN
YIN
Date

Allergies

Reaction

NKMA O

Date

Signature(s)
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Initials

Requisition Hepatitis C
Patient Information
Name:

Physician Information:
XXX

---------------------------Last

**Diagnosis reqnired**

M

F

ICD-9 Diagnosis
Chronic hepatitis C virus without
hepatic coma

Results Will be

XXXIXXX
Co to:
Date Ordered:

by location

other labs fax to XXX-XXX-XXXX

Routine Testing:

Other:

o

Complete Blood Count w/diff
(CBC)
0 Hepatitis C RNA Quant
(HCVRNAQ)
0 Hepatic Function Panel (HFP)
0 Comprehensive Metabolic Profile
(CMP)
0 Thyroid Stimulating
(TSH)
0 Pro time (PT)/INR
0 Iron Panel (IP)
(FER)
0
0 Uric Acid (URIC)
0 Triglycerides (TRIG)
0 Creatinine (CRE)
Chorionic Gonadotropin
0
(HCG) Serum
0 Human Chorionic Gonadotropin
(HCG) Urine

C genotype (HCVG)
B Surface antibody
(HBVSAB)
o Hepatitis B Surface Antigen
(HBVAG)
o Hepatitis A Antibodies (HAAR)
o
Smooth Muscle Antibody
(ASMA)
Anti Nuclear Antibody (ANA)
o Ceruloplasmin (CERUL)
o Alphafetoprotein (AFP)
o HIV YS: Antibody screen mV1I2AS
o Other:
Other:
o Other:

0
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Common Medication
Lab Work
Lab work is an important part of your chronic hepatitis C virus (HCV) therapy. Before and during
treatment, your doctor will do blood tests. These tests will check for side
and also tell you early on
how well treatment is
and how long you need to be on it. These tests may include a complete
blood count
viral load test,
panel, and liver function tests. You must stick to your lab
schedule because it is an
of your treatment for HCV.

Anemia
In your blood are red blood cells. Red Blood cells carry oxygen.
is needed throughout the
for
your muscles and organs to work properly. If your red blood cell counts become very low, you may have a
condition called anemia. Your healthcare provider (HCP) will check your red blood cell counts
periodically.
Anemia is measured with a simple blood test. The blood test may show the amount of hemoglobin in a
blood sample. The blood test may also report the hematocrit- the amount of red blood cells in a blood
sample. Both values help to inform your HCP on the severity of anemia.
The normal levels for these blood tests are different in men and women. For women, a normal lab value for
and a normal hematocrit is > 36%. For men normal lab value for hemoglobin is >
hemoglobin is> 12
13 gldL and a normal hemocrit is > 39.

Nutrition
It is important to maintain
nutrition while on chronic
C therapy to help provide your body
with the nutrients it needs. Your medical plan should include healthy food and drink choices and moderate
exercise. Exercise not only
you build muscles, it also helps your body fight off illness and it can
improve your mood and your "IJIJ":;"""'.

Taste Alteration
During treatment for
you may notice that food tastes different. This is called UYO•.,"',J:>ta
GOOZ-ee-a), or taste alteration. Food may taste different or it can taste bad. There are things that you can
do that may make this easier to live with. After you are done with
you should notice that your
sense of taste returns in about 2 to 12 weeks.

Flu-like Symptoms: General Information
Many people feel like they have the flu after they take their chronic
C medicine. You may have a
fever, a headache, and muscle aches that start several hours or days after treatment. Some of these
symptoms (fever,
may lessen after a few weeks as your body
used to the medicine.
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Flu-like Symptoms: Headaches
You may get headaches when you start treatment for chromc hepatitis C. They often start in the first 4 to 8
hours after treatment. Your headaches may lessen after a few weeks, once your body gets used to the
treatment.
First, it is important to understand what things can lead to headaches. You may get headaches after not
drinking enough water, not eating enough, stress, sleep problems, or too much or too little caffeine. There
are also some medical conditions that can lead to headaches, such as history of migraines, high blood
pressure, dental problems/jaw pain, allergies, sinus infection, and other problems. Talk to your healthcare
provider (HCP) about what may lead to your headaches and what you can do to manage them.

Nausea
You may feel "sick to the stomach", "queasy", or have an "upset stomach". This is called nausea. It can
happen because you are taking chronic hepatitis C medication or because of the chronic hepatitis C itself.
You may also have more saliva (spit); dizziness; light-headedness; trouble swallowing; cold, clammy skin;
and a fast heart rate. You may feel the worst during the first month or so of treatment, while the body gets
used to the medication.
Nausea is one of the common side effects of chronic hepatitis C therapy. Ask your HCP for a complete list
of side effects.
Nausea is different for everyone. You might be a little queasy or you may feel very sick. Talk to your HCP
if this feeling doesn't allow you to do things you do every day or if it is hard to take your treatment.
Nausea can come from other things like stress, headaches, other viruses or bacteria, alcoholic beverages, or
eating too little or too much. Figuring out things that bring on your nausea can help you and your HCP
control it. Some easy steps can make a big difference in how you feel.

Fatigue
People being treated for chromc hepatitis C often feel tired (also known as fatigued). In fact, 65% of people
said that they felt fatigued while being treated for chronic hepatitis C. If you are fatigued, you may feel
tired, weak, worn out, and unable to get out of bed. Also, you may not feel like doing anything, even the
things you once enjoyed, and you may feel down. You may notice these feelings getting worse throughout
the day. Fatigue may also be a symptom of depression. Talk to your healthcare provider (HCP) about your
fatigue and if you think you may be depressed.
It may help to know that you are not alone - many people with chronic hepatitis C also experience fatigue.
Of course, it is important to talk to your HCP about how much energy you have. That way, he or she can
give you ways to help.
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Problem
Date

I

Problem

Recommendations

Date Resolved

(see
effect
management
# below)

i
i

1

Common Side
Effects
Itching/Rash

2

Insomnia

3
4
5

Fatigue
Rectal discomfort
Poor
appetite/Nausea
Taste Alteration
Muscle aches

6
7

8
9

irritability
Hair thinning

Management Suggestions
apply hydrocortisone as needed,
Bedtime routines, avoid caffeine in the evenings, warm
showers, low
Conserve energy, rest periods during day
Keep area clean and dry, apply OTC hydrocortisone as n",,~r..::.n
Small meal portions, anti-nausea medications as prescribed,
ginger hard candies.
Y2 banana or chocolate may help, avoid metal utensils
Tylenol (limit to <2000mg/day), drink plenty of fluids,
symptoms, take medications as prescribed,
activities (reading, music, low impact .'",,,,'rn',,"
stress
I Sideofeff,ect of medication, nothing can be done to slow
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BIOPSY INSTRUCTIONS
Appointment

---------------------------

Time:

----------------------

PRE-BIOPSY INSTRUCTIONS

1.

Arrive 10-15 minutes
your appointment time, provided that you have completed
the necessary paperwork
signed
consent
home.
2. Do not take any
or
cornalnmg aspirin
48-hours or preferably one
week before
biopsy.
us of any significant bleeding history or clotting problems you
3. Please
observed. Our radiologist will review your blood tests (PT, PTT) to ensure normalcy.
Tbis test must be performed witbin six (6) montbs of your biopsy_ If you bave bad
tbis test done witbin six montbs, please tell our staff where and wben it was done. If

not, you win

to bave tbis test done before your biopsy.

4.

Assume a
diet
between 2-4 hours prior to biopsy and
diet for 2 hours prior to the biopsy.
dependent diabetICS:
5. For
breakfast, take usual insulin
a. If eating usual diet
liquids: hold a.m. T".,.r_"r·.,
is only
b. If

only a

liquid

take usual a.m.

intermediate or long-acting insulin dose.
CARE AFTER LIVER BIOPSY

instructions are recommended as
safeguard against
Please follow them
1.
As desired
nausea,
all food
1 hour then start with
liquids. Progress to
2. If you
full liquids, then a light bland diet, then a regular
Any """'An<>t""i'i drinks should be
room temperature.
3.
the local
wears
you may
pain and soreness. Occasionally, you
may experience referred
in your neck and/or right shoulder. If you need medication
you may take acetaminophen products
as
or ibuprofen
24 to 48 hours.
products such as Advil, Nuprin, Motrin, etc. Do not take aspirin
your biopsy,
remainder of the day.
next day you may return to work or
4.
other light activities if they do not involve lifting or straining. A void strenuous
for 48 hours:
runnmg,
lifting,
headed ness or
5. If you experience excessive bleeding or pain at the
heartbeat upon standing,
or
the
C treatment clinic at (213) 728-1887.
or she will
6. Your doctor will
the pathology results in approximately 7 days and
them
you.
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Exam Letter

Dear Doctor:
We would like to thank you for
our patient
an ophthalmologic exam. He/she is
scheduled to begin treatment with pegylated interferon for chronic hepatitis C infection.
with
has
associated:
.. Retinal
or vein thrombosis
.. Retinal hemorrhages
.. Cotton-wool spots
..
neuritis
.. Papilledema.
of this,
that all patients
an
examination
at baseline. Furthermore, the FDA
that
with pre-existing
ophthalmologic disorders (e.g. diabetic or hypersensitive retinopathy) should also
periodic ophthalmologist exams during their interferon alpha treatment.
jJ,",,,':U-l",",

TP£"PH'P

..

there are pre-existing ophthalmologic findings?
o Recommend exam at three (3) month
until the completion
of treatment (this can range from 24-48 weeks).

..

If you do not
o

problems

Recommend exam if changes in vision are reported

If you have any questions or comments,
free to contact us at ..
,,~We would appreciate a faxed ophthalmology evaluation to XXX-XXX-XXXX.
>J ....

Hepatitis C Care

119

.. >-L

Care Provider
PATIENT:~

_ _ _ _ __

Hepatitis C
Healthcare Provider:
We are currently
your patient for hepatitis C treatment.
on the patients
HCV genotype, the treatment course will require
up to 48 weeks. These
medications potentially cause a wide range of side effects.
we ,."",."'''''''T you to do to

There are certain
on
treatment.
____ . The patient

no

a psychiatric

''-'fiL..,.''..F,

1-' ....

patient prior to going

or by a psychiatrist.

a dilated
exam to
that he/she
retmc'Datnv as this treatment can eX~lcelrbate that.

_ _ 3. The patient would
would be able to
artery \.&1",,",,,,.,,",

to have a cardiac
to be certain that hislher
anemia conditions and not
pre-existing coronary

_ _4. The patient must

all alcohol and illicit

nearly 40%
Hepatitis
disease L./"":v..>. 1999) and leads to rapid
admitting to
per day oj alcohol

for at least six months.

UJfJrrlf'.,rll

with alcoholic liver
oJliver fibrosis in

1999)

stabilized, this includes
5. We would
co-morbid
such as diabetes, hypertension, and thyroid "",,,'"''''''''...,.

VAU,,,",,",,",,

If the marked
evaluation to rI",lr"'1"1""
ribavirin, and
therapy is initiated,
scheduled visits to

has chronic pain issues,
to be monitored closely
prior to going on hepatitis C treatment.

have been
will undergo final
for hepatitis C treatment
pegylated Int~·rtprnn
...,.",'tA·''''''''' inhibitor for
known genotype 1.
are checked frequently and
is monitored
by

aU.... HJ'VU,UU

If you have any
Sincerely, Hepatitis C

this regard, please do not u,",~."... ,.,", to call.
Team
120

C Education Session

C Education .... '-'.;,.""',,,

Re:

Dear
C Care Team
you to attend an \"'........."... VllUI
risks for
understand
include discussions on
medical treatment
HCV treatment.
and monitoring

.">'-' ",.">

".n I which

HUJll"'I.'U.;).;)IVU

The next class will be held on _ _ _ _ _ _ _ _ _ at _ _ _ _ _ _ am/pm in the
clinic "",nTp.,."",,,,,, room on x:xxx
We ", ... ,.",,,~ . . ,,,,,, you to bring a
you

any questions,

C

AU"" . . AV'"''

or a friend along with

to

Team
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Psychological Referral Letter

Mental

Provider:

above mentioned patient is being
for treatment of Hepatitis C with
pegylated interferon
ribavirin. The treatment is rigorous and difficult. One of the
major
effects
medication is an increase in depression, anxiety, irritability,
occasionally an increase in pain.
We
they
well as

as
in
who
psychiatric
as
active
healthcare providers to whom they can tum
additional help as
social support.
team would
you to
this
to
the stress
for up to 48 weeks. In addition, we would
to work
with your patient to formulate a plan care that
probable increased contact with
Please fax the psychiatric clearance to: XXX-XXXa
for
period of

xxxx
We
your
assistance. If you
contact our support staff at: XXX-XXX -XXXX

Sincerely,
Hepatitis C

Team
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any questions, please

free to

HCV Clinic No Response
Date - - - - - - - -

Hepatitis C Treatment Clinic Referral
Dear
a
from
pnmary care
to schedule you an appointment. At your
appointment we will be gathering basic
health
and providing you
on hepatitis
We
attempted to contact your by phone and
been unsuccessful in scheduling
XXXthis appointment. If you are interested in scheduling this initial session please

We encourage you bring a

family member or a friend

Hepatitis C Care
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with you.

Appendix P
ne]:lal111S

C realm em Clinic Announcement

Hepatitis C Treatment Clinic Announcement Letter

Date:
To:
From:
SUbject:

2,2012
Medical Staff
Medical
Infection Prevention & Control
Chief Medical Officer
Hepatitis C Clinic

We are in the process of establishing a Hepatitis C Clinic at the Ambulatory Infusion Center. We have
to see a few
to
a better idea what the work load will be to better establish staffing
.rprnpn,t<! as we gear up for
numbers of patients. To get a better of idea of those anticipated
numbers, we would request that you fax any referrals.

At the time of referral, please send us a recent history and physical with an up to date medication list.
Please have an ultrasound or CT scan of the liver done in the 12 months prior to the referral and also
have the following lab work done within
of the referral:
• Complete Blood Count w/diff (CBCD)
• Hepatitis C RNA Quant (HCVQRNA)
• Comprehensive Metabolic Profile (CMP)
• Protime (PT)/INR
• Iron Panel (lBCPRO) and Ferritin
Also, the following:
• Hepatitis C genotype (HCVG) - once only, no time frame
• HIV 1/2 Antibody Screen (HIV1/2AS) - within 12 months

Please manage the expectations of the patients you send us regarding:
I)
Timeliness oj appointments. We have a limited capacity to see and treat patients at this time,
although we expect that to change when we increase """".nu,,,,
2)
Likelihood ojreceiving treatment. There are significant number of contraindications and relative
contraindications to treatment and thus not all patients will be candidates for it at the time of
referral.

3)

be "hc'hnpnt
6 months
uncontrolled
transplant
or other conditions known to be exacerbated by interferon or ribavirin
•
disease
•
Severe concurrent disease such as severe hypertension, heart failure,
coronary
artery
poorly controlled
obstructive
disease
•
Known hypersensitivity to drugs used to treat HCV.
Treatment can be difficult, both because of their requirements for very high level of compliance
with the medications combined with the fact that
have significant side effects.

UpToDate has a number of good review articles on this subject,
1) Overview of the management of chronic hepatitis C virus infection
2) Patient selection for antiviral
for chronic hepatitis C virus infection
3) Patient information, both basic and beyond the basics
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ppelJQlX

Q

Hepatitis C Initiative Outcome

."'v'...........

C Initiative Outcome Survey

Additional

1. How many

o
o
o

0
11-20

-30
o >30
2. How likely are you to ",,,,,..T,.,,..,rn
hepatitis C "'.....,,"'-....,"..,_'" a~sse~ssrrlenr!

o

o

3. How likely are
profile
hepatitis
OVery
o Likely
o Somewhat
o Unlikely
4. How likely are
i Based
C
i
0
Very likely
o Likely
o Somewhat

5. How likely are you to refer a paIllem for
hepatitis C treatment?
o Very Likely
o Likely
o Somewhat unlikely
o Unlikely
6. How likely were you to encounter
in getting your patients ..",T'''' ....~'rI
C treatment?
o Very likely
o Likely
o Somewhat likely
o Unlikel
7. How likely will the community
hepatitis C treatment clinic
your
ability to care for your
o Very likely
o Likely
o Somewhat likely
o Unlikely
8.
0
0

o

0

Comments:

Thank you for your
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You are currently
prImary care
You are currently
specialty

ma

Appendix R
Pictorial

the Hepatitis C Initiative Timeline

Pictorial of the Hepatitis C Initiative Timeline

2002-2008
Sow the Seeds of Innovation

February 2010 HCV Steering Committee
(DNP student as Advocate)

July 2010
Institutional Taskforce Meeting
(DNP student as Educator)

July 20lO-April 2011
Community Needs Assessment and
Literature Review
(DNP student as Scholar)

April 2011
Community Taskforce Meeting
(DNP student as leadership)

October 2011
Program Implementation
(DNP student as Clinician)
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Appendix S
Pictorial of the Hepatitis C Initiative Future Research

Pictorial of the Hepatitis C Initiative Future Research

April 2012 Project Completion
(DNP opportunities for future research)
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